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resumo 
 
 
A absorção de radiação na região espectral do infravermelho médio fornece 
informações detalhadas sobre a composição química das amostras biológicas. 
A maioria das espécies moleculares absorve a luz infravermelha, que dá 
origem a padrões espectrais característicos na luz transmitida. As condições 
patológicas estão associadas a perturbações do metabolismo, que se refletem 
em alterações homeostáticas dos componentes moleculares das células e dos 
tecidos. O potencial clínico da espectroscopia de infravermelho por 
transformada de Fourier (FTIR) para detetar tais mudanças e o seu uso como 
uma ferramenta de diagnóstico tem recebido cada vez mais atenção. Esta 
técnica permite a identificação de sinais associados à demência, a um nível 
bioquímico, e auxilia na identificação de biomarcadores específicos.  
Esta dissertação é um estudo exploratório que pretendeu testar a capacidade 
da espectroscopia FTIR para discriminar amostras de indivíduos controlo de 
amostras de possíveis doentes de Alzheimer, e identificar sinais 
espectroscópicos correspondentes a grupos funcionais de biomarcadores 
presentes no soro e no plasma relativos à doença.  
As amostras de sangue foram colhidas e os voluntários do estudo foram 
submetidos à avaliação cognitiva através do Mini Exame do Estado Mental 
(MEEM) e da Escala de Avaliação Clínica da Demência (CDR). Informações 
clínicas relevantes também foram recolhidas. As amostras dos possíveis 
doentes de Alzheimer, assim como as amostras dos controlos pareados com a 
mesma idade e sexo foram analisadas por FTIR. Os espectros na gama de 
4000-900 cm
-1
 foram submetidos à análise em componentes principais (ACP).  
Com o diagrama das coordenadas fatoriais (scores) do PCA foi possível 
discriminar os espectros das amostras de possíveis doentes de Alzheimer dos 
espectros das amostras dos controlos. O diagrama das contribuições fatoriais 
(loadings) permitiu a identificação de sinais espectroscópicos associados a 
grupos funcionais de biomarcadores envolvidos na discriminação entre 
amostras de doentes e controlos.  
Futuramente, após a recolha de todos os sinais espectroscópicos 
correspondentes aos biomarcadores de AD e de definir o (s) biomarcadores 
responsável (eis) pela identificação espectroscópica de AD, será possível 
desenvolver um modelo de classificação multivariada. 
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abstract 
 
The absorption of radiation in the mid-infrared spectral region provides 
detailed information on the chemical composition of biological samples. Most 
molecular species absorbs infrared light, giving rise to distinctive spectral 
patterns in transmitted light. The pathological conditions are associated with 
metabolic disorders that are reflected in homeostatic changes of molecular 
components of cells and tissues. The clinical potential of Fourier Transform 
Infrared (FTIR) spectroscopy to detect such changes and its use as a 
diagnostic tool has received increasing attention. This technique allows the 
identification of signals associated with dementia at a biochemical level, and 
helps to identify specific biomarkers.  
This dissertation is an exploratory study, which aimed to test the ability of 
FTIR to discriminate between control and Alzheimer’s Disease (AD) samples 
and to identify spectroscopic signals spectroscopic signals corresponding to 
functional groups of biomarkers present in serum and plasma of the disease.  
Blood samples were collected and volunteers of the study were submitted to 
cognitive evaluation through Mini Mental State Examination (MMSE) and 
Clinical Dementia Rating (CDR). Relevant clinical information was also 
collected. Samples of putative Alzheimer's patients, as well as samples of the 
controls matched by age and sex were analyzed by FTIR. Spectra in the 
range 4000-900 cm
-1
 were submitted to Principal Component Analysis (PCA).  
With the diagram of the factorial coordinates (scores) of the PCA was possible 
to discriminate the sample spectra of putative Alzheimer's patients, of the 
sample spectra of controls. The diagram of the factorial contributions 
(loadings) allowed the identification of spectroscopic signals associated with 
functional groups of biomarkers involved in discrimination between samples 
from patients and controls.  
In future, after matching all spectroscopic signals of the corresponding AD 
biomarkers and gathering biomarker (s) responsible for the spectroscopic 
identification of AD will be possible to develop a model of multivariate 
classification. 
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Chapters overview 
 
Chapter 1 
This chapter gives an overview of Alzheimer's disease, its diagnosis methodologies and the most 
studied biomarkers. It also presents the FTIR technique as a tool to investigate new biomarkers. 
 
Chapter 2 
This chapter gives an overview of FTIR principles and it aims to discuss the intense water 
contribution in mid-infrared spectrum of serum and plasma samples, providing an optimized 
experimental methodology to overcome this problem. 
 
Chapter 3 
This chapter presents the results on the application of FT-IR spectroscopy to the plasma and 
serum samples of putative Alzheimer’s patients, and controls matched by age and sex, in order to 
identify spectral differences that help discriminate between the two groups. 
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I. Epidemiology of Alzheimer’s disease 
 
Dementia is one of the major causes of disability in later life. It accounts for 11.9% of the years 
lived with disability due to a non communicable disease. It is the leading cause of dependency and 
disability among older people (1,2). 
Alzheimer’s disease is the most common form of dementia and possibly contributes to 60–70% 
of cases of dementia. Other major contributors include vascular dementia (VaD) contributing with 
20% of the cases, dementia with Lewy bodies (DLB) with a frequency of 30-40%, frontotemporal 
dementia (FTD) explaining 3%-10% of demented individuals and dementia in Parkinson’s disease 
(PDD), whose frequency is lower (1–3). Mixed pathologies are also very common, particularly for 
AD and VaD, and AD and DLB (2). Mild Cognitive Impairment (MCI) is a pre-demented state highly 
associated with progression to AD or other dementia.  
There are approximately 35.6 million people living with dementia worldwide today. This 
number is likely to double by 2030, and triplicate by 2050. In addition, Alzheimer’s is becoming a 
more common cause of death (1). About 2% to 10% of all dementia cases start before the age of 
65, and the likelihood of developing dementia roughly doubles every five years (2). Due to 
women’s longer life expectancy, it is difficult distinguish the risk to develop AD between women 
and men (1). The total worldwide costs estimated for dementia were US$ 604 billion in 2010 (2). 
In Portugal it is estimated that there are around 153,000 people with dementia, among them 
90,000 with AD (4). At the moment, because of the economic crisis, dementia is not one of the 
political priorities (5). As consequence, both the general population and health professionals have 
scarce information, and the latter are not sensitive for early diagnosis, devaluating often the 
symptoms and interpreting them as part of the normal aging process. This lack of awareness leads 
to a more pronounced progression of symptoms because patients do not receive appropriate care 
in good time (6). 
Given the global impact of disease, Alzheimer’s disease is recognized as a priority, and a special 
attentions to the needs for improve early diagnosis was declared by European Parliament (6). 
II.  Pathology of AD  
 
The outcome of Alzheimer’s disease is dementia that typically begins as a progressive loss of 
episodic memory. Subsequently, a possible disconnection between cortical areas occurs due to 
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progressive deterioration in cognitive and adaptive functioning, leading to the next characteristic 
symptoms of dementia such as impairment of thinking, orientation and language, and other 
dementia-related symptoms (7). 
1. Hallmarks of AD  
Although the brain of an Alzheimer’s disease patient shows a typical symmetric pattern of 
cortical atrophy mainly at the medial temporal lobes that can be recognized early in the clinical 
course of the disease by MRI scan, so far, the definitive diagnosis of AD is only made post mortem 
through the histological examination of the brain (8).  
Although other neuropathological lesions are encountered in AD cases, the two primary 
cardinal lesions associated with Alzheimer’s disease are the senile plaques (SPs) and the 
neurofibrillary tangles (NFTs) (7). Thus, demented individuals who do not have plaques and 
tangles does not qualify for a diagnosis of AD, but the simple presence of plaques and tangles do 
not distinguish demented from nondemented individuals since brains of aged nondemented 
individuals frequently contain plaques and tangles (9). Instead, fundamental characteristics that 
define the neuropathological entity of AD are the spatiotemporal pattern of deposition of both 
SPs and NFTs (7). 
1.1. Neurofibrillary tangles (NFTs) 
Neurofibrillary tangles (NFTs) are considered to be a major pathological hallmark of 
Alzheimer’s disease. However, presence of NFTs per se is not sufficient to diagnose AD since it 
may also be encountered in association with many other chronic neurological diseases (8). 
Neurofibrillary tangles are developed within the pyramidal neuronal soma, and then extend 
into the neuronal processes. Apparently, NFTs are primarily made of paired helical filaments 
(PHFs) that are fibrils of approximately 10 nm in diameter that form pairs with a helical 
tridimensional conformation. However, other structures may also constitute the NFTs such as 
fibrils with appearance of straight filaments (8). 
The primary constituent of the neurofibrillary tangles is the microtubule-associated protein tau 
abnormally phosphorylated (P-tau) at very specific protein sites (8). Tau protein is involved in 
cytoskeletal functions and has a critical role in microtubule stabilization and in the efficiency of 
the synapse (10). Therefore, contribution of tau to AD pathology is mainly due to its loss of 
function, as well as gain of toxic function such as aggregation and deposition as neurofibrillary 
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tangles (11). In addition to tau protein, other protein constituents are associated with the 
neurofibrillary tangle, such as ubiquitin, cholinesterases and beta-amyloid (Aβ) (8). 
Remarkably, NFTs have a stereotypical spatiotemporal progression that correlates with both 
the degree of dementia and the duration of illness (8). Briefly, the neurofibrillary degeneration 
starts in the allocortex of the medial temporal lobe (entorhinal cortex and hippocampus) leading 
to loss of memory and then spreads to the associative isocortex leading to disconnection between 
cortical areas. The primary sensory, motor, and visual areas are relatively spared (Figure 1) (8,12). 
 
 
 
Figure 1. Spatiotemporal pattern of neurofibrillary degeneration. Shading indicates the distribution of 
NFTs with darker colors representing increasing densities. Amyg: Amygdala; EC: Entorhinal cortex; CA1: 
Cornus ammonis 1 hippocampal subfield; Cg: Cingulate cortex; Prec: Precuneus; 4 = Primary motor 
cortex; 3-1-2 = Primary sensory cortex; 17 = Primary visual cortex; 18 = Associative visual córtex; 
Adapted from (8). 
 
1.2. Senile Plaques (SPs)  
The other cardinal pathological lesion encountered in patients suffering from Alzheimer’s 
disease is the neuritic or senile plaque (SP).  
SPs are constituted by extracellular deposits of enlarged axons, synaptic terminals and 
dendrites, associated with insoluble Aβ peptide in the parenchyma of the brain (8).  
SPs result from the abnormal extracellular accumulation and deposition of the Aβ. Moreover, 
several forms of Aβ-containing plaques may be present in the brains of aged individuals and AD 
patients. Among them, diffuse or immature plaques that consist of Aβ in a non-aggregated form, 
free of any neuritic involvement, are often in brains of elderly healthy. On the other hand, dense-
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core plaques which are consequence of the neurite dystrophy that occurs due to Aβ deposits, are 
characteristics of brains of AD patients (8,13). 
Ultra-structurally, the dense-core plaques are comprised of a central mass of extracelullar 
filaments that radially extend toward the periphery. In periphery, filaments intermingle with 
neuronal, astrocytic, and microglial processes. The neuronal processes, known as dystrophic 
neuritis (DN), often contain PHFs, abnormal mitochondria and dense bodies of apparent 
mitochondrial and lysosomal origin (8). 
Topographically, the amyloid deposits accumulate first in isocortical areas, followed by limbic 
and allocortical structures, and, in a later stage, by subcortical structures including basal ganglia, 
selected nuclei in diencephalon and brainstem, and the cerebellar cortex (Figure 2) (8). Likewise 
NFTs, among the isocortical areas, primary sensory, motor, and visual areas tend to be less 
affected as compared to association multimodal areas (12). 
 
 
Figure 2. Spatiotemporal pattern of amyloid plaque deposition. Coronal (A), axial (B), and sagittal (C) 
views of the brain. Areas in red are the first areas of deposition, the second affected areas are in orange 
and last areas are represented in yellow. Amyg: Amygdala; EC: Entorhinal cortex; Hipp: Hippocampus; 
Cg: Cingulate cortex; Cd: Caudate nucleus; Put: Putamen; Gpe: Globus pallidus externus; Gpi: Globus 
pallidus internus; Cl: Claustrum; Ins: Insular cortex; Die: Diencephalon; Mid: Midbrain; Med: Medulla 
oblongata; Cblm: Cerebellum; Adapted from (8,14). 
 
Clinical-autopsy correlation studies demonstrate a much tighter correlation between 
neurofibrillary pathology and cognitive impairment than between amyloid pathology and 
cognitive impairment (8). Thereby, Aβ pathology is thought to develop first during the long 
preclinical phase, whereas the neurodegenerative pathology, including NFTs formation and 
neuronal or synapse loss, accelerates slightly before the appearance of the symptomatic phase of 
AD (15). 
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NFTs and SPs are detected with staining techniques or with specific antibodies directed against 
hyper-phosphorylated tau to detect NFTs and against Aβ to detect SPs. Since DNs often contains 
PHFs, antibodies directed against P-tau can be used to detect SPs (Figure 3) (16). 
 
 
Figure 3. Neurofibrillary tangles and Aβ plaques in temporal cortex of patients with Alzheimer’s 
disease. Use of modified Bielschowski stain to visualize neurofibrillary tangles (A) and neuritic plaques 
(B); Immunohistochemical preparation using antibodies directed against tau tangles (C) and Aβ plaques 
(D); Antibody directed against neurofibrillary tangles (red arrow) also detects dystrophic neuritis (black 
arrow) (E). Adapted from (8,16). 
 
1.3. Other neuropathological lesions in AD 
Since Aβ peptide also tends to deposit in the walls of the cerebral cortical blood vessels, 
cerebral amyloid angiopathy (CAA) is another feature possibly present in AD brain that may lead 
to spontaneous vascular rupture, and bleeding (16). Granulovacuolar degeneration (GVD) and 
Hirano bodies are two poorly understood lesions present in the cytoplasm of hippocampal 
pyramidal neurons of AD patients. While GVD have a possible role in tangle formation and in the 
apoptosis, Hirano bodies have unknown significance (8). Other lesions are reactive astrocytes and 
activated microglial cells that are trigged either by Aβ as by neurofibrillary degeneration (8).  
Indeed, the main pathological substrates of cortical atrophy are loss of neurons  and of 
neuron-to-neuron communications (synapses) that constitute the major morphological 
counterparts to cognitive loss in Alzheimer’s disease, with a better correlation with cognitive 
deficits than number of NFTs (8,16).  
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2. Genetics of AD 
AD is genetic and clinically heterogeneous and is usually classified according to its age of onset. 
Therefore, early-onset AD (<5% of cases) occurs before 65 years and is often the familial form 
associated with an inheritance autosomal dominant pattern, and late-onset AD (>95% of cases) 
occurs in subjects over 65 years of age and is more frequently of sporadic origin (17). 
2.1. Familial AD 
To date, three genes have been identified whose mutations cause the early-onset familial AD 
(EOFAD) with full penetrance. These genes are the amyloid precursor protein (APP) gene in 
chromosome 21 (with 10-15% of EOFAD cases), the presenilin 1 (PSEN1) gene in chromosome 14 
(with 20-15% of EOFAD), and the presenilin 2 (PSEN2) gene in chromosome 1 (more rarely 
affected)(17,18).  APP is a larger transmembrane protein maybe implicated in synapse formation, 
neural plasticity and iron export (19–21),  whose amyloid metabolism originates the Aβ peptide. 
Presenilin (PS) is the major component of the γ-secretase, an enzymatic complex that performs 
the second cleavage of APP (22). 
2.2.  Sporadic AD 
Contrary to familial AD, in most sporadic AD cases, with a complex etiology, genetic factors act 
as predisposing agents which taken alone are not often enough to develop the disease. Thus, to 
exert their pathogenic effect, specific genes probably interact with environmental risk factors 
such as head trauma, social engagement and diet, or with other pathologic conditions including 
cardiovascular disease and MCI, or with physiologic risk conditions such as advanced age (1).  
Apoliprotein E (ApoE) is the major lipoprotein throughout the brain expressed by astrocytes, 
under physiologic conditions, or by neurons, under stress (10). This apoliprotein participates in 
the distribution and metabolism of cholesterol and triglycerides. Among its isoforms, the ɛ4 allele 
of the apolipoprotein E (ApoE ɛ4) is the major genetic risk factor for both early-onset AD and late-
onset sporadic cases (LOAD) (23).  ApoE ɛ4 allele strongly affects deposition of Aβ to form senile 
plaques and also contributes to AD pathogenesis by Aβ-independent mechanisms such as synaptic 
plasticity, cholesterol homeostasis, neurovascular functions, and neuroinflammation (23). 
Comparing with ApoE ɛ4 non carriers with a frequency of 20% to develop AD, in subjects 
heterozygous the frequency of Alzheimer's disease is about 47% and in homozygous is about 91%. 
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Furthermore, the clinical onset with an earlier age is dramatically increased in a gene dose-
dependent manner (23). 
Only less than 50% of sporadic AD cases are carriers of the ApoE ɛ4 allele. Therefore, other 
susceptibility genes related with Aβ metabolism, tau phosphorylation or synaptic transmission 
must be involved in the pathogenesis of the sporadic cases of the disease (17).  
3. Pathogenesis of AD 
Although the exact etiology and pathogenesis of AD still remains obscure, it is believed that 
several factors interact and are overlapped pathways that increase the capacity of injury in 
specific brain regions and circuits involved in memory and language (hippocampus and cerebral 
cortex), resulting in a progressive cognitive deficit. 
The preeminent hypothesis of AD pathogenesis is based on the amyloid cascade hypothesis, in 
which Aβ is the key player (24). In addition, other interveners have some weight in neuronal loss 
and progression of damage and cognitive decline, including oxidative stress, lysosomal 
dysfunction, signaling pathways alteration and vascular risk factors (10,25).  Neurotransmitters 
such as glutamate, acetylcholine, dopamine, and serotonin are also dysfunctional (10,25) and are 
the main targets to current therapeutic strategies. 
3.1. Aβ Genesis 
Aβ peptide is a proteolytic cleavage final product of APP, which in turn can undergo proteolytic 
processing by one of two pathways (Figure 4).  
Most of APP is processed through the non-amyloidogenic pathway. In the later, APP suffers its 
first cleavage by α-secretase (ADAM 9, 10 or 17) yielding the membrane-anchored α-carboxy 
terminal fragment (C83) and the ectodomain sAPPα that may have neuroprotective roles. Then, 
C83 is cleaved by γ-secretase releasing P3 peptide and APP intracellular domain (AICD), which 
prevents the generation and release of the Aβ peptide. On the other hand, APP molecules that 
are not cleaved by the non-amyloidogenic pathway follow the amyloidogenic pathway and 
become a substrate for the β-secretase (BACE1), releasing the sAPPβ and membrane-anchored β-
carboxy terminal fragment (C99). C99 is subsequently cleaved 38–43 amino acids from the amino 
terminus to release Aβ by the γ-secretase complex, comprising presenilin 1 (PS-1) or 2 (PS-2), 
nicastrin (NCSTN), presenilin enhancer 2 (PEN2) and anterior pharynx defective (APH-1) (22,26). 
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Figure 4. The two pathways of APP proteolysis. Non amyloidogenic (background blue) and 
amyloidogenic (background beige) pathways for APP processing. Adapted from (22,26). 
 
Under physiological conditions, Aβ1–40 is the most predominant peptide that can be eliminated 
from the brain due to its soluble features. In contrast, Aβ1–42 is the predominant monomer in AD 
that is highly fibrinogenic, difficult to degrade, and with tendency to aggregate in soluble toxic 
oligomers called amyloid-β-derived diffusible ligands (ADDLs) (27).  
 
3.2. The amyloid cascade hypothesis  
Amyloid cascade hypothesis is the one that best explains the AD pathogenesis and suggests 
that Aβ1–42 aggregation initiate the pathogenic cascade that leads to neuronal loss (Figure 5). 
Accumulation of Aβ1–42 is due to imbalance between the levels of Aβ production, aggregation 
and clearance (28). Thereby, its overproduction may be promoted by mutations in the APP, PSEN1 
or PSEN2 genes. The ability of Aβ1–42 monomers to aggregate is enhanced by failures in its 
enzymatic degradation and clearance, and, under pathological conditions, can accumulate into 
potentially toxic oligomers and/or plaques (24,28). In turn, oligomers can also be sequestered into 
plaques, also due to failures in degradation and clearance of Aβ1–42. Oligomers may be the toxic 
Aβ species that contribute to de-regulation of signaling pathways, resulting in formation of PHFs 
of tau, which in turn are very difficult to degrade (24). PHFs accumulation directly affects 
intracellular transport, leading to synaptic damage accompanied by neuronal loss (24,28).  
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Figure 5. The amyloid cascade hypothesis. ADDLs: Amyloid-β-derived diffusible ligands. Adapted from (24,28). 
 
3.3. Oxidative stress  
Oxidative stress is other prominent pathological change in the AD brain and occurs when 
excessive generation of reactive oxygen species (ROS) during normal metabolic processes in the 
cell is unbalanced by the antioxidative defense system.  
Mitochondrial oxidative phosphorylation is the major source of ROS like the hydrogen 
peroxide radicals (H2O2), hydroxyl radicals (OH
.) and the superoxide radical (O2-.) that are very 
unstable and highly reactive. ROS increase lipid peroxidation, leading to alteration of the 
membrane properties of the cell  such as fluidity, ion transport, enzyme activities, and protein 
cross-linking (22). The oxidative damage that ensues is seen in lipids, proteins, nucleic acids, and 
sugars, all of which are organic compounds essential for the structural and functional integrity of 
neurons. 
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Brain tissue is highly susceptible to ROS damage because neurons require high-energy support 
and the oxidative processes lead to dysfunction of mitochondria. Furthermore, brain tissue is rich 
in easily peroxidizable unsaturated fatty acids (mainly arachidonic and docosahexaenoic acids) 
and has a high content of iron, that is important to lipoperoxidization reactions (29).  
Several studies suggest that oxidative stress is involved in Aβ fibrillization and NFT formation in 
AD, and in turn the Aβ also increases oxidative stress. Thereby it is created a vicious cycle of ROS 
generation that far exceeds the antioxidant defense system. Hence, oxidative stress is, 
undoubtedly,  a contributing factor for neuronal death in AD (22). 
3.3.1. Oxidative stress and dysfunction of the autophagy and the apoptosis   
Autophagy is a homeostatic process involved in the turnover of proteins and cell organelles 
and has an important role in the regulation of cell destiny after stress injury. This process is a non-
lethal stress response mechanism. The lysosome, an intracellular organelle completely devoted to 
the degradation or recycling of intra and extracellular components, is the main player of this 
process (22). Apoptosis is a type of programmed cell death regulated in an orderly way by a series 
of signal cascades. Apoptosis plays an essential role in regulating growth, development, immune 
response and eliminating excess or abnormal cells in organisms. However, the up-regulation of 
apoptotic process leads to increase of cell death and can result in neurodegeneration if occur in 
neuron cells (22).    
In lysosomes, a failure to degrade aggregated Aβ1–42 may contribute to intracellular 
accumulation of Aβ in AD (30). In addition, the intracellular Aβ1–42 is resistant to protease 
degradation and stable within the neurons, this may invokes the rapid ROS generation within 
lysosomes and disruption of lysosomal membrane that leads to a lysosomal general dysfunction. 
Lysosomal dysfunction leads to accumulation of unfolded proteins that can also induce stress in 
endoplasmic reticulum (ER). Between other consequences, ER stress can increase γ-secretase 
activity that consequently enhances the Aβ secretion (22,31). In addition, ER and mitochondria 
are in close communication, and ER stress, occurring in AD brain, can be expanded to the 
mitochondria, where are triggered pathways of cell death by apoptosis (31). Some studies have 
also demonstrated the direct and indirect involvement of Aβ in the activation of the apoptotic 
pathway. The direct mechanism by which Aβ causes apoptosis is by inducing specific caspases (8 
and 9) that lead to neuronal death. By the indirect mechanism, Aβ promotes membrane lipid 
peroxidation that also leads to apoptosis (32). In sum, lysosomal dysfunction mediated by Aβ can 
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lead to stress of ER and mitochondria, which in turn leads to production of more Aβ and 
activation of apoptosis that culminates in neurodegeneration (30).  
 
3.4. Signaling alteration 
 One of the most relevant aspects for signal transduction in AD pathology is protein 
phosphorylation.  Phosphorylation refers to the addition of a phosphate to one of the amino acid 
side chains of a protein by kinases and removal of the same group by phosphatases. The addition 
and removal of a phosphate group to the structure of the protein alters its function, and this 
balanced process serves multiples roles in the regulation of cell function.  
However, the imbalance of protein kinases and phosphatases, contribute to abnormal 
activation of signaling pathways, which can be a cause or consequence of many diseases, 
including AD.  
In the brain, phosphorylated Aβ aggregates could serve as endogenous seeds, triggering 
further aggregation of soluble and extracellular Aβ into plaques (33). In turn, the Aβ can lead to 
abnormal protein phosphorylation, and subsequent abnormal signaling cascades (34). The 
abnormal activation of signaling pathways may promote abnormal phosphorylation and 
aggregation of tau and cytoskeletal abnormalities. This might lead to synaptic failure, altered 
neurogenesis and apoptosis, typical of AD pathogenesis (28). Abnormal phosphorylation levels of 
APP have been also reported in AD (33,34), as well as other AD associated proteins such as PSs 
and BACE (33). 
3.5. Vascular risk factors  
Vascular risk factors such as hypertension, atherosclerosis, hyperlipidemia, metabolic 
syndrome, diabetes, obesity, ApoE ε4 and inflammation are risk factors that increase the 
propensity to AD and accelerate its progression (35). In turn, insulin resistance and type 2 
diabetes increase the risk of cardiovascular disease and stroke that, consequently is associated 
with AD (36).   
Vascular risk factors together with advancing age create a progressive degeneration in cerebral 
capillaries that may lead to a severe state of hypoperfusion – critically attained threshold of 
cerebral hypoperfusion (CATCH) – which in turn may lead to the cellular and subcellular pathology 
underlying to the manifestations of AD (10,25). In addition, it seems that Aβ peptide have a 
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vasoconstrictor effect that also leads to hypoperfusion that precedes onset of clinical dementia 
(10).  
Cholesterol: The dysregulation of cholesterol homeostasis in the brain, mainly related to 
increased levels of cholesterol in plasma, takes a place in AD pathogenesis. Apparently, 
cholesterol loading increases γ-secretase activity and amyloidogenic pathway, while low 
intracellular cholesterol favors non-amyloidogenic pathway  (25,37). ApoE is the major cholesterol 
carrier in the brain and the inheritance of the ApoE ε4 allele was associated with elevated 
cholesterol levels. Indeed, presence of the ApoE ε4 allele is associated with increased amyloid 
burden, decreased Aβ peptide degradation, and less effective neuronal repair mechanisms (38). 
Inflammatory changes: Microglia, astrocytes and possibly neurons are involved in the 
inflammatory process in AD. Aβ can activate microglia which leads to an increase of pro-
inflammatory cytokines such as TNF-α and IFN-γ, which in turn induce expression of nitric oxide 
synthase resulting in neuronal damage. Similarly, astrocytes, due to its agglomeration at sites of 
Aβ deposits, and neurons, by expression of higher levels of classical pathway complement and 
pro-inflammatory products, are able to trigger inflammatory processes (25).  
 
Cerebral insulin resistance: AD is also considered a metabolic disease that results in 
progressive impairment in the brain's capacity to utilize glucose and respond to insulin stimulation 
(39). Cerebral insulin resistance can be due to peripheral insulin resistance, e.g. due to Diabetes 
Mellitus (DM) 2 type, or can be due to toxicity induced by ADDLs (39). In turn, insulin might 
increase extraneuronal accumulation of Aβ. This insulin effect is due to the competition between 
insulin and Aβ for insulin degrading enzyme (IDE) that is involved in the degradation of both of 
them (25).  
In addition, it was shown that the expression and activity of IDE is significantly decreased in AD 
brains and that IDE and Aβ are deposited in neuritic plaques and vessels. This also leads to: 
increase of insulin resistance; insufficient degradation of insulin and Aβ; formation of Aβ 
oligomers; and neurodegeneration (10).  
Glycation of proteins is another consequence of insulin resistance due to increased levels of 
sugars. Hyperglycemia promotes protein glycation and the gradual accumulation of advanced 
glycation end-products (AGEs) in body tissues (40). AGEs comprise molecules formed by 
irreversible, non-enzymatic reactions between sugars and the free amino groups of proteins, 
lipids and nucleic acids (41). In fact, it was found high levels of AGEs in AD brains, even in neurons 
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where Aβ is absent, suggesting that glycation is risk factor to AD (40). Both the occurrence of 
insulin resistance in AD and hyperglicemia suggest that DM 2 type might not only be involved in 
CATCH (42), but also in hormonal and metabolic changes that also leads to AD (39). Therefore, 
these conditions might be closely related (41). 
III. Therapeutic strategies for AD 
Currently, AD treatment cannot stop the disease, but can slow down symptoms progression in 
some cases. Four medications, descript in Table 1, are approved by the U.S. Food and Drug 
Administration to treat Alzheimer's. All four AD drugs are available to patients in Portugal and are 
part of the reimbursement system (43). These drugs produce improvements in cognitive and 
behavioral symptoms, but their role in the pathogenesis of AD is unknown.  
Table 1. Approved medications by the U.S. Food and Drug Administration to treat Alzheimer's disease. Adapted from 
(44–47). 
AD pathology Drug name Drug type  Clinical phase  Action mechanism 
Failures in glutamate removal 
leads to its intracellular increase, 
leading to excitotoxicity, free 
radical production and then cell 
death.  
Namenda® 
(memantine) 
 NMDA 
antagonist  
Moderate to severe  Blocks the toxic effects 
associated with excess 
glutamate and 
regulates its activation 
Decrease of cholinergic 
receptors leads to dysfunction of 
cholinergic signals transmission 
resulting in failures of signaling 
between neurons, free radicals 
toxicity and inflammation and 
then neurodegeneration. 
Razadyne® 
(galantamine) 
Cholinesterase 
inhibitor  
Mild to moderate  Prevents the 
breakdown of Ach and 
stimulates nicotinic 
receptors to release 
more Ach in the brain 
Exelon® 
(rivastigmine) 
Cholinesterase 
inhibitor 
Mild to moderate Prevents the 
breakdown of Ach and 
butyrylcholine (a brain 
chemical similar to 
Ach) in the brain 
Aricept® 
(donepezil) 
Cholinesterase 
inhibitor  
Mild to moderate 
and 
Moderate to severe  
Prevents the 
breakdown of Ach in 
the brain 
NMDA, N-methyl D-aspartate; Ach, acetylcholine 
 
In recent years, several approaches aimed at inhibiting disease progression have advanced to 
clinical trials. The foci have been on reducing Aβ, by diminishing its accumulation or increasing its 
clearance, or by reducing tau deposition, by decreasing its synthesis or its phosphorylation.  
Other complementary and/or alternative strategies currently tested to protect selective 
neuronal populations include gene therapy, vaccination, intra-thecal drug delivery and use of 
compounds bound to lipids (28). Furthermore, strategies to promote synaptic formation and 
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neurogenesis are also attractive options to inhibit disease progression. Among them, cellular 
therapies are rapidly in expanding, aiming to transplant new neurons that integrate, synapse, and 
recapitulate a neural network similar to that lost in disease. In addition, the complementary use 
of stem cells may provide environmental enrichment to support host neurons by producing 
neurotrophic factors, scavenging toxic factors, or creating auxiliary neural networks around 
affected areas (22). 
 
IV. Diagnosis of AD 
 
1. Current guidelines 
The diagnosis of AD is usually based on criteria established in 1984 by National Institute of 
Neurological Disorders and Stroke–Alzheimer Disease and Related Disorders (NINCDS–ADRDA) 
(48). NINCDS-ADRDA criteria are based in the fact that clinical symptoms are in close 
correspondence with the pathologic changes of disease. However, this presupposition is not clear 
and is insufficient to detect dementia in a pre-dementia phase. This early detection is crucial for 
delay progression of dementia with appropriate therapies. 
In 2011 new criteria and guidelines incorporate some changes such as incorporation of 
biomarkers, formalization of different stages of disease and consideration of common coexistence 
of AD and other neurodegenerative diseases (7).  However, these criteria are currently intended 
mostly for research purposes due to the lack of standardization of biomarkers values (49). 
According to NINCDS-ADRDA guidelines of 1984 that still remain in force, the clinical diagnosis 
is only probabilistic and the definite diagnostic is only possible after histologic confirmation  (48).  
2. Typical clinical pattern of dementia related conditions 
AD diagnosis may be complicated by coexisting conditions or when symptoms and pathologies 
of various dementias overlap (2). Therefore, an accurate diagnosis will help patients receiving the 
treatment and support services appropriate for their condition and maintain the highest possible 
quality of life. The neuropathological characteristics and typical symptoms of AD and other 
common dementia related conditions are briefly describes in Table 2.  
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Table 2. Neuropathological characteristics and symptoms of the most common dementia related conditions.  
Condition Clinical and Imaging Hispathologic 
hallmarks 
Refs 
MCI  Impaired recent memory; 
 General cognition is preserved; 
 History or cognitive screening tests indicate mild memory failures; 
 MRI shows increased atrophy of the hippocampus and the parietal 
and lateral temporal regions. 
 Not completely 
characterized; 
 Amnestic MCI may 
be a forerunner of 
AD 
(3) 
AD  Loss of episodic memory; 
 Cognitive impairment (thinking, orientation, comprehension, 
calculation, learning capacity, language, and judgment); 
 Deterioration in emotional control, social behavior, or motivation 
 MRI shows increased atrophy involving medial, basal, and lateral 
temporal lobes and medial and lateral parietal cortices; 
 PET scans demonstrate glucose hypometabolism in 
superior/posterior temporal regions, and marked retention of PiB in 
the frontal, parietal, temporal, and occipital cortices. 
 Amyloid plaques 
outside the neuron; 
 Intracellular 
neurofibrillary 
tangles 
(2,3,10,50) 
VaD  Sudden post-stroke changes in thinking and perception (confusion, 
disorientation, trouble speaking or understanding speech and vision 
loss); 
 Cognitive and functional decline occurs gradually; 
 History of cardiovascular risk factors are suggestive of VaD; 
 CT or MRI scanning demonstrates areas of past infarction and 
perivascular ischaemia. 
 Cerebrovascular 
lesions; 
 Ischemic brain 
damage 
(3) 
DLB  Fluctuating cognition, visual hallucinations and parkinsonism; 
 Cognitive decline similar to AD, with memory impairment less 
prominent in early state, and apathy more remarkable; 
 MRI shows diffuse atrophy with less hippocampus atrophy than in 
AD; 
 SPECT or PET imaging shows reduced dopaminergic activity in basal 
ganglia. 
 α-synuclein 
immunoreactive 
protein deposits 
(Lewy bodies) in 
neurons and glial 
cells. 
 
(3,51,52) 
PDD  Parkinsonism, depression, psychosis and cognitive impairment;  
 Visuospatial functions affected;  
 Memory relatively preserved; 
 MRI shows no significant difference in whole brain and caudate 
nucleus between controls; 
  SPECT or PET imaging shows reduced dopaminergic activity in basal 
ganglia. 
 Lewy bodies, 
amyloid plaques 
and neurofibrillary 
tangles 
(53,54) 
FTD  Personality change and behavioural disturbance occur early and are 
prominent features; 
 Impulsiveness, poor financial judgment, inappropriate social 
conduct and declining interest in grooming and hygiene; 
 The age of onset is often between 50-60 years; Family history of 
FTD is a risk factor; 
 MRI shows focal degeneration within the anterior frontal, temporal, 
and insular regions; 
 PET or SPECT scanning show reduced brain activity in the frontal 
and anterior temporal regions. 
 Microtubule-
associated protein 
tau (FTLD-TAU) 
inclusions; 
 TAR DNA-binding 
protein-43 (FTLD-
TDP) inclusions; 
 Fused in sarcoma 
protein (FTLD-FUS) 
inclusions 
(3,55,56) 
MD  Vascular pathology may interact with preexisting subclinical AD, 
resulting in clinical dementia; 
 The severity of cognitive impairment is correlated to the total 
volume of infarcts; 
 There are no generally accepted and validated clinical and 
neuropathological guidelines for the diagnosis of MD; 
 Criteria for AD and VaD are of limited value for the diagnosis of MD. 
 Combination of AD 
with vascular or 
ischemic lesions 
 Neuropathological 
evaluation needs 
further validation 
(3,57) 
 MCI: Mild Cognitive Impairment; AD: Alzheimer’s Disease; VaD: Vascular Dementia; DLB: Dementia with Lewy Bodies; 
PDD: Parkinson's disease dementia; FTD: frontotemporal dementia; MD: Mixed Dementia 
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The signals and symptoms of each dementia condition allow for the differential diagnosis of 
dementia. Diagnosis of AD and other dementias is a stepwise process that involves clinical 
evaluation with examination of patient history and early warning signs, as well as 
neuropsychological assessments that comprise performance screening, assessment of daily 
functioning, behavioral problems, and caregiver status. Finally, it may be required a referral to 
specialist clinics for more thorough assessment that may include radiological and biological 
analyses (1,58). 
3. Clinical evaluation  
The first step of clinical evaluation relies on prediagnostic tests to investigate other conditions 
that mimic dementia and to determine coexisting disorders. For this should be considered the 
history of mental and behavioral symptoms, a physical examination, and laboratory findings 
through blood and urine analyses, and radiologic tests such as Magnetic Resonance Imaging (MRI) 
or Computed Tomography (CT) to help in the identification and to rule out other potential causes 
of dementia (48,58,59). 
The course of the disease is an individual process, however it should be noted that there are 
prevalent symptoms during disease progression. Even before the onset of cognitive problems, 
there are several warning signs that can predict those individuals at a higher risk of developing AD 
or other dementia. The American Alzheimer’s Association lists ten key warning signs of AD, 
including memory loss, difficulty performing familiar tasks, problems with language, 
disorientation to time and place, poor or decreased judgment, problems with abstract thought, 
misplacing things, changes in mood or behavior, changes in personality and loss of initiative (58), 
while conscious remains unaltered (2). Severe dementia frequently causes such complications as 
immobility, swallowing disorders and malnutrition. These complications can significantly increase 
the risk of developing pneumonia, the most commonly identified cause of death among elderly 
people with Alzheimer’s disease and other dementias (1). 
3.1. Neuropsychological tests 
To assess performance of patients some cognitive tests may be used to help in screening of 
AD, by discriminating patients with cognitive deficits from those without it, including the Mini-
mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), and Clock-
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drawing (60,61). The MMSE has reigned as the screening test as it is quick and easy to administer 
and can track the overall progression of cognitive decline per se (58).  
Activities of daily living should also be explored, and tests such as the Activities of Daily Living 
Scale (ADL) can determine the extent of the patient’s disability and dependence on the caregiver.  
More that 80% of AD patients experience some form of behavioral symptoms such as anxiety, 
agitation, depression, and apathy during the course of the disease. The common test to evaluate 
depression is the Geriatric Depression Scale (GDS) that helps to differentiate AD from depression 
(62). 
In addition, there are some tests that intend: acquire detailed profile of cognitive deficits such 
as Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog); evaluate staging of 
dementia, for example the Clinical Dementia Rating (CDR); and examine global changes such as 
Clinician Interview Based Impression of Change plus Caregiver Input (CIBIC-plus)  (61). Due to the 
wide variety of neuropsychological tests, this kind of evaluation is time consuming and is not 
available for all concerned people (59). In an attempt to increase the accuracy of diagnosis, still 
exists an urge to continue developing instruments of cognitive indicators more reliable in early 
dementia (63).  
3.2. Neuroimaging 
A variety of imaging techniques are available for evaluating the structural, biochemical, and 
functional changes of the brain that increase the accuracy of clinical diagnosis of 
neurodegenerative diseases. Conventional structural neuroimaging with CT or MRI is 
recommended in the routine evaluation of patients with memory disorders, to exclude treatable 
causes such as intracranial mass or vascular dementia and to help assess the degree of atrophy 
(48,64). Since brain structural alterations are most evident in latter stages of disease, the 
diagnostic potential of these techniques in early stages of AD is limited. 
There are other available imaging techniques that can also be used on suspicion of other 
dementia related condition. Functional imaging modalities, including single-photon emission 
computed tomography (SPECT) and positron emission tomography (PET), offer value in the 
differential diagnosis of dementia, particularly in distinguishing AD from VaD, FTD, DLB, and 
depression. Functional techniques also allow identifying more subtle pathologic changes earlier 
during the disease course than structural ones. 
Functional MRI (FMRI), magnetic resonance spectroscopy (MRS), single-photon emission 
computed tomography (SPECT), structural magnetic resonance imaging (MRI) and positron 
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emission tomography (PET) are the most used in research and/or diagnosis of Alzheimer’s disease 
and other dementia (Table 3). Since MRI and PET revealed more consistent results, they were 
introduced at the new criteria as biomarkers tools of AD.  
Table 3. Imaging approach in Alzheimer’s disease. 
Technique Alzheimer’s correlation References 
Strutural MRI  Atrophy involving medial, basal, and lateral temporal lobes and medial and 
lateral parietal cortices 
(7,59) 
Functional MRI  Pattern of altered activation in the medial temporal lobes and parietal lobes (22,59) 
1
H-MRS  Lower levels of NAA in the parietal gray matter and hippocampus  (22,50,59) 
PET   FDG–PET* scans demonstrate reduced glucose metabolism in the parietal and 
superior/posterior temporal regions 
(50) 
 11C-PiB PET** has marked retention in the frontal, parietal, temporal, and 
occipital cortices as well as the striatum, consistent with the pattern of amyloid 
plaque deposition 
(50,65) 
SPECT   Temporoparietal hypoperfusion or hypometabolism (50) 
NAA: N-acetylaspartate; 
PDG-PET*: fluorodeoxyglucose is a radiotracer analog of glucose 
11
C-PiB**: Pittsburgh compound B is a radiotracer capable of highlighting deposits of beta-amyloid in living individuals 
during a PET scan 
4. Genetic tests 
AD is mainly considered a sporadic pathology and, consequently, genetic screening cannot be 
largely utilized for its diagnosis. However, for the rare cases in which individuals have family 
members with early onset familial AD, genetic tests are available. These genetic screenings 
include testing for PSEN1, PSEN2, APP and APOE mutations, wherein PSEN1 and APOE mutations 
take the lead role.  
However, like predictive value of APOE ɛ4 homozygotes is as high as for many other Mendelian 
diseases, the APOE genotyping has gained greater importance as predictive potential. Thereby, 
APOE ɛ4 homozygotes have high risk of developing AD, heterozygotes have modest risk, and 
individuals who do not carry an APOE ɛ4 allele have low risk of developing AD (22). 
5. Alzheimer’s disease diagnosis in Portugal   
Similarly to other European countries, in Portugal, to assess patients with suspects of cognitive 
impairment or dementia, are performed clinical history evaluations, general physical examination 
including laboratory tests on blood (hemogram; glucose; calcium levels; serum ionogram; liver, 
kidney and thyroid functions; dosage of vitamin B12 and folic acid and serologic test for syphilis), 
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and neuropsychological tests with cognitive evaluation (MMSE and MoCA), assessment of 
activities of daily living (ADL) and depression rating (GDS)(43). 
In addition, structural imaging test such as CT or MRI, are used in order to exclude treatable 
causes of cognitive decline and to provide information for a diagnosis specific etiological (43). In 
atypical situations or when clinical features are suggestive of other diseases, the specialist may 
collect CSF samples for suspected cases of neoplastic involvement, inflammation or infection of 
the CNS, and SPECT can be used on suspicion of DLB (43). 
Genetic studies are performed if there is a family history of autosomal dominant disease or a 
phenotype suggestive. However, for most of the patients with sporadic Alzheimer's disease, the 
genetic study, mainly ApoE genotyping, is currently not recommended in clinical (43). 
 
V. Biomarkers as diagnostic tools for AD 
 
Since the early symptoms of the disease are shared by a variety of neuropathological disorders 
it is important to find markers  that assist in the diagnose and that help the monitoring of the 
disease progression (1,22,66). 
The ideal biomarker for the diagnosis of AD should be directed at its basic neuropathology and 
correlate with histological criteria for the diagnosis. Furthermore it should detect AD at an early 
asymptomatic stage and mark its presence by itself rather than a risk factor, as well as it should 
track severity of AD pathology at preclinical stage. In addition, the ideal biomarker should be also 
reliable, reproducible, non-invasive, inexpensive, and rapid. Not least, it should react upon 
pharmacological intervention and display high sensitivity (>80%) and specificity (>80%) for the 
disease as compared with related disorders (67). 
Five biomarkers (Table 4) that have been widely studied,  were now formally incorporated into 
the diagnostic criteria of AD (7). These comprise: structural brain changes visible on structural 
magnetic resonance imaging (MRI); molecular neuroimaging changes seen with positron emission 
tomography (PET); and concentration changes of Aβ1-42 and tau in the cerebrospinal fluid (CSF) (7). 
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Table 4. Currently accepted biomarkers for the diagnosis of Alzheimer's disease. These biomarkers were grouped into 
two broad categories agreed by National Institute on Aging. Adapted from (7). 
 Biomarkers category Category description Biomarkers for AD Diagnosis 
Biomarkers of Aβ 
accumulation 
Indicative of initiating or 
upstream events which seem 
to be most dynamic before 
clinical symptoms 
 Abnormal tracer retention on amyloid PET (11C-PiB) 
imaging 
 Low CSF Aβ1-42 
Biomarkers of neuronal 
degeneration or injury 
Indicative of downstream 
pathophysiological processes 
which become dynamic later 
 Elevated CSF tau (T-tau and P-tau) 
 Decreased fluorodeoxyglucose uptake on PET (FDG-
PET)  in a specific topographic pattern involving 
temporoparietal cortex 
 Atrophy on structural MRI—again in a specific 
topographic pattern—involving medial, basal, and 
lateral temporal lobes and medial and lateral 
parietal cortices 
 
The role of biomarkers differs somewhat in each of the disease phases. Figure 6 shows a 
hypothetical relation of the biomarkers of AD with phases of disease. In the preclinical phase 
(cognitively normal) begins the most of the molecular alteration observed in AD and biomarkers 
are used to establish the presence of the pathophysiological process, aiming a better care for AD 
patients.  In this phase, Aβ can be measured by PET-amyloid and CSF Aβ biomarkers, and neuronal 
injury and degeneration are detected by CSF tau and FDG-PET biomarkers (68). 
In the symptomatic predementia/MCI phase, biomarkers are used to establish the underlying 
etiology responsible for the clinical deficit and to assess the likelihood of disease progression. In 
this phase, characterized by a little recent memory impaired, can also be measured Aβ and 
neuronal injury and degeneration and some atrophy of the brain is detected by MRI (68). 
In the dementia phase, the neuropsychological tests disclose impairment of the memory and 
cognition, and biomarkers are used to increase or decrease the level of certainty of the 
pathophysiological process underlies the dementia due to AD (68). 
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Figure 6. Illustrative model of the ordering of biomarkers of AD relative to stages in the clinical onset 
and progression of AD. Clinical phases are on the horizontal axis. The vertical axis relates, in function of 
the disease progression, the appearance of the hallmarks of disease, the morphological alterations of 
the brain, the memory loss and the increased general clinical dysfunction. Adapted from (68). 
 
1. CSF biomarkers  
The lumbar puncture to collect cerebrospinal fluid is an invasive procedure that hinders 
obtaining this fluid for analysis. However, CSF is a very useful fluid for AD diagnosis since it reflects 
metabolic process in the brain due to the direct contact between the brain and CSF. Furthermore, 
CSF biological modifications seem to appear before first modifications seen on MRI (69).  
Among the high numbers of CSF brain-derived proteins undergoing investigation, three 
biomarkers, all soluble in CSF, were validated internationally and included in AD diagnosis criteria: 
low Aβ1-42, high total Tau (T-Tau) and high phospho-Tau-181 (P-Tau) (22,59,67). This core of 
biomarkers reflects AD pathology, and has high diagnostic accuracy to diagnose AD in dementia 
and symptomatic predementia phase (59,70). 
Investigating levels of key Alzheimer-related proteins in cerebrospinal fluid (CSF) is largely 
researched due to inconsistence of the proteins levels from institution to institution. To facilitate 
consistency and move this vital area forward, the American Alzheimer’s Association has funded 
the Alzheimer's Association QC Program for CSF Biomarkers, wherein organizations can improve 
their analytic capabilities by comparing their outcomes to results at reference laboratories in the 
United States and Europe (54). 
Aβ1-42 peptide: In AD patients the CSF concentration of soluble Aβ1-42 decreases, suggesting that 
this may be due to the preferential deposition of Aβ peptides into cerebral amyloid plaques with 
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lower levels diffusing to CSF (59). CSF Aβ1-42 concentration may differentiate AD patients from 
controls with high sensitivity (86%) and specificity (90%). ELISA measurements indicate a range of 
values between 600 and 1230 pg/mL to normal subjects and between 260 and 500 pg/mL to AD 
patients (59,70) 
Tau protein: Increase of CSF tau total (T-tau) levels is not AD specific since it is also observed in 
other dementia types, in which neuronal death occurs. However, CSF T-tau levels are around 150 
– 450 pg/mL in normal subjects and range 300 – 1100 pg/mL in AD patients (59,70). 
Phosphorilated Tau protein: CSF P-tau species might specifically mark a cerebral degenerative 
process because its increasing levels are correlated with cognitive decline. The most commonly 
used ELISA methods for P-tau in CSF use antibodies for phosphorylation at either threonine 181 
(P-tau181) or threonine 231 (P-tau231), thus improving accuracy of biological diagnosis. P-tau181 
levels are between 30 and 50 pg/mL in normal subjects, and between 75 and 100 in AD patients 
(59,70). 
Combination of Tau and Aβ: It has been suggested that the use of combinations of these three 
CSF markers could have more successfully to discriminate AD from control or other forms of 
dementia than an individual marker, wherein the high CSF P-tau/ Aβ1-42 ratio possesses the higher 
diagnosis accuracy (71). 
Although these biomarkers are recognized in Portugal, is still not used in clinical evaluation 
(43,72), since its standardization is hampered, implying that each centre establishes its own 
reference values (72). 
A recent Portuguese study evaluated CSF biomarkers in AD and in pre-dementia stages, and in 
agreement with previous publications, confirmed that CSF biomarkers, namely the Aβ1-42/p-Tau, 
are accurate tools (specificity and sensitivity above 85%) for the diagnosis of AD and may be 
useful in the identification of MCI patients (72). Given the invasive character of CSF collection, the 
investigations become restricted and, at moment, its diagnostic use in Portugal is limited. 
Therefore, there is a need to find more viable options in more peripheral fluids. 
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2. Fluid biomarkers to detect Alzheimer’s disease under 
investigation 
2.1. CSF biomarkers 
Apart from Aβ1-42, T-tau and P-tau181, numerous other molecules have been investigated as 
biological CSF promising markers and are liable to participate on etiological dementia diagnosis. 
Some of them that seem to supply advantage for differential and early diagnosis include: Aβ1-
42/Aβ1-40, Aβ1-42/Aβ1-38 and Aβ1-42/Aβ1-16 ratios that may give slightly higher accuracy than Aβ1-42 
alone; the high concentrations of ADDLs in AD patients compared with controls. In addition, 
BACE1 may also be a CSF promising marker, given that upregulation of β-secretase is an early 
event of AD (70,71). 
Neuronal and synaptic proteins are also research targets as AD biomarkers, wherein the 
calcium sensor VLP1 and the synaptic protein GAP-43 have demonstrated to be high in AD 
patients than in controls, and neurofilaments are often in normal concentrations compared with 
VaD or FTD patients (70,71). 
The oxidative stress AD markers in CSF include high levels of F2-isoprostanes compared to 
healthy controls or patients with other dementia. Possible markers of neuroinflammation include 
acute-phase protein α-ACT that is either increased or unchanged in CSF samples of AD patients, 
and cytokines (interleukins, TNFα, Interferon-γ and TGF-β) (70,71). 
2.2. Blood biomarkers 
Although plasma biomarkers as reliable markers for AD diagnose have met little success, some 
molecules have been investigated, and some of them can be used to evaluate AD prediction, 
progression and therapeutic monitoring. For example, high plasma levels of Aβ1-42 were suggested 
to be a risk factor for developing AD, and Aβ measures are potentially used in clinical studies to 
therapeutic monitoring that affect APP processing. However, plasma Aβ measures are not 
sensitive or specific markers for diagnosis of AD (73). This is probably explained by the fact that 
the major plasma Aβ is derived from peripheral tissues and does not reflect brain Aβ production. 
Furthermore, the hydrophobic nature of Aβ makes the peptide bind to plasma proteins, which 
could result in epitope masking and other analytical interferences (70,71). On the other hand, 
quantification of platelet APP isoforms holds promise for tracking diagnosis, progression, and 
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treatment effects (73). Indeed, mononuclear leukocytes seem to offer a stable medium to 
determine β-sheet structure levels as a function of AD development (74). 
Increased markers of oxidation of protein, lipid, and nucleic acid and reduced activities of 
antioxidant enzymes are according to neurodegeneration in AD and are also in plasma/serum. 
Plasma/serum antioxidants include carotene, lycopene, vitamin A, C and E, urate and bilirubin. 
ROS damage of protein, polyunsaturated fatty acids and nucleic acids are markers of oxidative 
state and was associated with AD pathology (31,73). Among stress oxidative markers, 
malondialdehyde (MDA), 8- hydroxy-2′-deoxyguanosine (8-OHdG) and F2-isopropanes were the 
most promising (59). 
Reactive inflammatory responses are consequences of amyloid deposition, and AD may be 
associated with the immune dysregulation, detectable in plasma (73). Furthermore, two proteins 
present in SPs, α2-Macroglobulin (α2M) and complement factor H (CFH), and increased levels of 
α1 antitrypsin, α1-antichymotrypsin, and decreased levels of apolipoprotein A1 in plasma/serum 
were observed in AD patients compared with healthy controls. However, these differences have 
not yet attained the sensitivity, specificity and reproducibility to become AD biomarkers (71). 
Additionally, it was found 18 signaling proteins in blood plasma that can be used to classify 
samples from Alzheimer's and control subjects with high accuracy and to identify patients who 
had MCI that progressed to AD. Further independent studies are needed to verify this 
combination of plasma biomarkers and their diagnostic value (75). 
2.3. Biomarkers of other biological fluids  
Among several biological fluids, a special attention is accorded to saliva and urine. Although 
urine has the obvious advantage of easy collection, is a limited source of biomarkers due to its 
very low protein concentrations and high salt levels (71). However, neural thread protein (NTP) 
levels have been consistently identified as a possible AD biomarker in urine, and its levels increase 
with disease severity (71). Similarly, saliva is simple to obtain and has the property that may 
reflect changes in CSF. Therefore, in a pilot study (76), it was suggest that saliva Aβ1-42 levels could 
be considered a potential peripheral marker for detect early AD with an additional ability to 
discriminate AD from other types of neurodegenerative disorders.  
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3. Strategies for novel biomarkers discovery in neurological 
disease 
Identification of biomarkers in neurological disease remains impeded by many obstacles. There 
are four basic challenges to biomarker identification in neurological disease. The first is the lack of 
availability of tissue at the site of pathology ante-mortem that hinders the discovering 
etiologically relevant genes, proteins or small molecules to diagnose the disease. The second is 
that clinical diagnostics are poor in information, and the state in which the disease is diagnosed is 
usually advanced, being the definitive diagnoses of neurodegenerative disease only achieved 
upon autopsy. The third challenge is the complexity and tissue heterogeneity that is more 
accentuated in the brain than in other organs resulting in transcriptomes, proteomes, 
morphological phenotypes and interactive connections widely variables within the neurons and 
glial cells. The fourth challenge is the paucity of model systems for functional validation in 
neurological diseases that hinders the confirmation of candidate biomarkers, because 
neurological diseases are mainly behavioral in nature, therefore it is difficult to ascertain many of 
the phenotypic characteristics as they occur in vitro or in vivo (animal models) (77). 
Ideally, a systematic approach to biomarker identification will involve multiple “-omic” 
technologies to investigate the disease process at all levels. Genomics is used to identify relevant 
disease genes, aberrant cellular signaling pathways, and expression signatures correlated with 
disease. Proteomics is used to identify aberrant protein expression, post-translational 
modification, protein interactions, and protein profiles that are specific to a particular disorder. 
Finally, metabolomics is implemented to identify the presence of abnormal levels of small 
molecule metabolites that are specific to and indicative of an underlying disease process (67,77) 
Given this, and the multiplicity of processes implicated in AD, the diagnostic accuracy of 
biomarkers may be improved by combining several serum or plasma markers in order to create a 
more robust biomarker profiling characteristic of AD (73). 
3.1.  A focus on metabolomics techniques  
The metabolome is the sum of all low molecular weight metabolites in a biological system and 
metabolomics refers to its analysis. Metabolomics has begun to have a more prominent role in 
efforts at biomarker identification and will increasingly be applied to neurological disorders. 
Metabolomics is typically performed on biofluids, such as serum, urine, saliva and CSF (77). 
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By assessing hundreds of metabolites simultaneously, metabolomics techniques produce high-
resolution biochemical snapshots showing the functional endpoints of genetic predisposition as 
well as the sum of all environmental influences such as nutrition and medication. This snapshot 
can provide an almost real-time image of the pathophysiology of an entire organism, which it is 
not possible obtain in genomics, proteomics or in other “-omics” (78). Specifically, due to the fact 
that any biochemical change must precede any morphological manifestation of the disease itself, 
the metabolomic approach may be very useful for early diagnosis. 
Metabolomics is a multi-disciplinary science that requires analytical techniques such as 
chromatography, molecular spectroscopy or mass spectrometry, coupled with bioinformatics 
tools such as multivariate data analysis methods, to get the most out of the data.  
There are three major approaches used in metabolomics studies: targeted analysis; metabolite 
profiling; and metabolic fingerprinting (79). 
Targeted analysis is used to quantify a limited number of known/target metabolites precisely 
(79). Metabolite profiling restricts itself to a certain range of compounds or even to screening a 
pre-defined number of members of a compound class. For these two approaches, main 
techniques are gas chromatography (GC), high performance liquid chromatography (HPLC) and 
MRS, which rely on chromatographic separations, often coupled with well-developed calibrations 
for specific analytes (80). 
Metabolic fingerprinting does not attempt to identify or precisely quantify all the metabolites 
in the sample. Rather, it considers a total profile, or fingerprint, as a unique pattern characterizing 
a snapshot of the metabolism in a particular cell line or tissue. The metabolic fingerprinting is 
most useful in biomarker discovery and diagnostics, namely to discover specific metabolic 
patterns of diseases.  
Mass spectrometry (MS) and Fourier transform infrared (FTIR) spectroscopy (or other 
spectroscopic techniques) are usually used in fingerprinting for directly acquire spectra without 
any separation step such as chromatography or electrophoresis (79).  
  
3.2. The potential of the FTIR as clinical tool 
FTIR is a technique almost universal because many molecules have strong absorbances in the 
mid-infrared region, and is applicable for many types of samples (solids, liquids, gases and pasts. It 
is highly versatile, since is needed minimum sample preparation. Infrared spectra are information 
rich, wherein peaks positions give the information about the structure of molecules in a sample. 
29 
 
The intensity of peaks is related to the concentration of molecules and peak widths are sensitive 
to the chemical matrix of the sample (pH and hydrogen bonding).  
Given that FTIR spectroscopy is a technique based on metabolomics is able to detect 
biochemical changes caused by pathologies, even at a very early stage of the disease. In addition, 
comparing with other laboratory instruments (e.g. for NMR, GC-MS or LC-MS) infrared 
spectrometer is relatively inexpensive (81).  It gives the opportunity to analyze, in real time, small 
amount of sample, providing reliable and reproducible spectral data (82). Whilst it is not as 
specific and sensitive as other techniques of metabolomics such as GC-Tof-MS, it has been 
recognized as a valuable tool for metabolic fingerprinting, owning to its simplicity and ability to 
analyze several biomolecules simultaneously (83). 
FTIR has been applied to samples of human tissue and body fluids and has shown potential to 
support clinical pathology, i.e. detecting and grading of disease (84,85). In this context FTIR 
spectroscopy proved to have potential in cancer diagnosis (86–88) such as cervical cancer (89), 
colorectal cancer (90), liver cancer (91), prostate cancer (92,93) and breast cancer (94). The 
diagnosis and evaluation of the chemotherapeutic efficacy of patients with leukemia was also 
achieved with this technique (95,96). Others applications include diagnosing arthritic disorders 
(97,98) and determination of kidney complex stones composition (99,100). Infrared spectroscopy 
has also proved to be a valuable tool for characterizing and differentiating microbial cells (101), 
proving a rapid method for identifying micro-organisms responsible for human infections (102). In 
addition, FT-IR has proved to be very useful to understand the mechanism of atherosclerosis 
development (103,104) and the diabetes diagnosis (105,106). It also can be used to the 
determination of the concentrations of metabolites in whole blood, plasma and urine (107–110). 
With particular relevance, FTIR has been used in neurological disorders, wherein the quest for 
diagnosing Alzheimer’s disease has a considerable role. Thereby, studies showed its potential use 
in the diagnosis of AD from autopsy tissue (111). More recently has been investigated its potential 
for early diagnosis, using biofluids such as CSF (112) and parts of blood including plasma and 
leukocytes (74,113). In the study with CSF, it was found a high diagnostic accuracy, corresponding 
to Aβ and tau protein identification. In plasma samples, it was possible to associate oxidative 
stress in AD groups (113) and in the mononuclear leukocytes of peripheral blood, it was found 
spectroscopic regions mainly associated with Aβ peptide (74). 
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VI. Significance of the study  
Alzheimer’s disease is the major cause of cognitive impairment and subsequent dementia, in 
the elderly. As life expectancy tends to increase, AD is becoming a greater health problem with 
many costs associated. Therefore, there is a need to early, simple and cost-effective diagnosis of 
AD in order to apply correct therapies that slowed cognitive decline. An early diagnosis, in the MCI 
phase, may delay the onset of Alzheimer's dementia (114). 
At present, the most reliable and sensitive diagnostic techniques are invasive, hindering its 
clinical implementation. Blood-based tests are an appealing alternative because of its simplicity 
and reduced cost-effectiveness in clinical application. However, to date, the biomarkers 
investigated in blood of AD patients have reduced sensitivity and specificity for AD diagnosis (59). 
Given the multiplicity of pathophysiologic processes involved in AD, a multi-analyte profiling 
approach to plasma/serum contents can yield biologically important signatures of disease to allow 
for diagnostic accuracy, prognosis and novel therapeutic development (73,115,116). 
Metabolomics showed to be a valuable tool for the identification of molecular mechanisms 
involved in the etiology of AD, wherein plasma was validated as a reliable biofluid for metabolic 
studies of brain-related disorders, resembling the profiles in CSF (115). In turn, FTIR spectroscopy 
is a valuable metabolic fingerprinting tool, simple and with minimal needs of sample preparation 
that has been shown promising results for diagnostics of many pathologic conditions (84).  
Given the small sample size of this study, it is impracticable define if obtained data constitute a 
biologically relevant effect. Therefore, here it will be carried out an exploratory study or a pilot 
study. This kind of studies aims to the generation of data that suggest hypotheses for more 
intensive and targeted confirmatory experiments in the future (117).  
Considering that plasma/serum samples are aqueous samples and that water absorbs IR 
radiation strongly, the spectra interpretation may be difficult due to the band overlap. Thus, a 
specific aim of this study is remove water signals using drying of the samples under controlled 
conditions by a procedure called drying kinetics. Chapter 2 aims to present this methodology 
applied in plasma and serum. 
Chapter 3 presents a direct analysis of serum and plasma spectra in order to exhaustively 
identify and assign the spectroscopic bands. Here it is also discussed the limitations of the direct 
spectra analysis to accurate discrimination between spectra of putative AD patients and 
corresponding age and sex matched controls and the key role of multivariate analysis (PCA) to this 
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achievement. Finally, it is intended the identification of spectroscopic signals, arising from the 
functional groups of possible biomarkers, involved in the discrimination of the putative AD and 
controls.  
Therefore, the exploratory study presented here specifically aims to: 
1) test the ability of FTIR to analyze plasma and serum samples, after overcoming water band 
overlap; 
2) test the ability of FTIR together with multivariate analysis (PCA) to discriminate between 
non-AD and putative AD patients, using plasma and serum samples; 
3) identify spectroscopic signals and assign functional groups of possible biomarkers in 
plasma and serum samples that discriminate non-demented controls from the putative AD 
patients; 
4) establish conditions of spectroscopic analysis for serum and plasma samples; 
5) establish the type of sample, either serum or plasma, that best distinguishes the non-
demented controls from the putative AD patients. 
With this exploratory study it is hoped to contribute to a future development of objective and 
sensitive methodology for the diagnosis of Alzheimer’s disease, based on spectroscopy and 
multivariate analysis.  
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I. Method overview and experimental conditions 
optimization 
1. General considerations on infrared spectroscopy  
Spectroscopy is based on the interaction between sample and electromagnetic radiation, to 
perform an analysis of individual chemical components including proteins, nucleic acids and 
metabolites, and provides detailed information about the structure and mechanism of action of 
molecules (81). 
The type of spectroscopy depends on the interaction that different frequencies of 
electromagnetic radiation have with the molecules. With different radiation is possible to extract 
information of the energies of electronic, vibrational and rotational states, structure and 
symmetry of molecules as well as dynamic information. Among spectroscopic techniques, those 
with great utility to biomedicine include NMR, infrared, Raman, UV/Vis circular dichroism and 
fluorescence spectroscopy (118). 
The infrared (IR) radiation of electromagnetic spectrum is invisible to the naked eye, its 
wavenumber range lies between 14000 and 4 cm–1 and is responsible for molecular vibrations. 
Energy frequencies higher than 14000 cm–1 (ultraviolet and visible light) cause electronic 
transitions, while energy frequencies lower than 4 cm–1 (microwaves) create the molecular 
rotations (Figure 7) (81). 
The IR spectrum can be subdivided into near-infrared (NIR) region between 14000 and 4000 
cm-1, mid-infrared (MIR) region between 4000 and 400 cm-1, and far-infrared (FIR) region between 
400 and 4 cm-1 (81). When MIR radiation is used in infrared spectroscopy it is possible to obtain 
valuable information about sample chemical composition. When NIR radiation is used in 
spectroscopy the spectral information obtained is more difficult to interpret due to the 
characteristics of spectroscopic signals that are fewer and broader (81).  
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Figure 7. The IR regions of the electromagnetic spectrum. Adapted from (81,119). 
 
1.1. Vibrations of molecules  
The molecular bonds are not rigid, and do not have fixed lengths. Instead the nuclei 
oscillate/vibrate about their mean positions. 
A molecule consisting of n atoms has a total of 3 n degrees of freedom, corresponding to the 
Cartesian coordinates (x, y and z) of each atom in the molecule. In a nonlinear molecule, 3 of 
these degrees are rotational and 3 are translational, whereas the remaining corresponds to 
fundamental modes of vibration. In a linear molecule, 2 degrees are rotational and 3 are 
translational. Therefore, the fundamental vibrations for nonlinear molecules are 3n – 6, and 3n – 
5 for linear molecules (120). For example, H2O molecule has three (3(3) – 6) molecular vibrations, 
while CO2 has four fundamental modes of vibration (3(3) – 5).  
The molecular vibrations can be classified into axial deformation (stretching) and angular 
deformation (bending). A vibration of axial deformation is a rhythmic movement along the axis of 
the molecular bond that can be symmetric or asymmetric (Figure 8). The vibrations of angular 
deformation correspond to rhythmical variations of molecular bonds that have an atom in 
common, or the movement of a group of atoms relative to the rest of the molecule with no 
changes in the relative positions of the atoms of those groups. The vibrations of angular 
deformation involve changes in bond angles in relation to an arbitrary coordinate ensemble of the 
molecule. Four vibrational modes of angular deformation (bend) include scissoring (symmetrical 
bend in-plane), rocking (asymmetrical bend in-plane), wagging (symmetrical bend out-of-plane) 
and twisting (asymmetrical bend out-of-plane) (Figure 8). 
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Figure 8. Examples of vibrational modes of stretching and bending. Adapted from (121). 
 
Not all vibrations of the molecules are observed in the IR spectrum. The IR absorption process 
involves absorption of energy by the molecule if the vibration causes a change in the dipole 
moment of the molecule (120). There is a dipole moment when there is a difference in 
electronegativities of the bonded atoms. When the oscillating electric field, induced by the 
vibration of the atoms in the molecule, interacts with the radiation appears a peak in the infrared 
spectrum. If there is no variation, there will be no oscillating field to interact with radiation, and 
no radiation will be absorbed or emitted (120). Thus, while homonuclear diatomic molecules (H2, 
N2, and O2) have no dipole moment because the two identical atoms have identical 
electronegativities, heteronuclear diatomic molecules (HCl, NO, and CO) have dipole moments, so 
they have IR active vibrations (120). Likewise, the same molecule may have vibrations that are 
active in IR and other inactive. For example, the symmetric stretching mode of CO2 is inactive in 
IR, because this vibration does not break the symmetry of the molecule and, thus, the dipole 
moment remains zero. There are also molecules such as H2O that have all its fundamental modes 
of vibration active in IR. 
Since a molecule can have many vibrational active modes, the use of mixtures makes spectrum 
highly complex and difficult to analyze due to the several overlaps of bands (81). When applying 
FTIR to biomedical samples such as tissues or body fluids, one the major obstacles is the large 
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water content. Furthermore, even with no water signals, a peak may have several assignments 
and the same functional group may give signals at different sites of the spectrum. 
1.2. FTIR equipment 
A spectrometer comprises a light source, an optical system, a detector and a sample holder. 
Radiant energy from source is directed to the sample and a detector measures the intensity of the 
emergent beam. 
FTIR is the predominant type of infrared spectrometer in use and have advantages and 
disadvantages when compared to other types of spectrometers (81).  
One of the major advantages of FTIR over other spectrometers is their ability to acquire 
spectra with high signal-to-noise ratios (SNRs). SNR values are due to some spectrometer 
characteristics like: throughput, multiplex and wavenumber precision. The throughput advantage 
is attributable to high-intensity of infrared beam that arrives to the detector, increasing the signal 
level. The advantage of multiplex is related to the possibility of co-adding scans, another way of 
improving SNR of a spectrum. Finally, the high precision is due to the laser that acts as an internal 
wavenumber standard. High SNRs increase the sensitivity of the instrument, and allow 
quantitative accuracy, increasing the possibilities of applications (81).   
Artifacts are one of the FTIRs disadvantages. There are peaks present in the spectrum that are 
not from the sample, some of them are caused by the atmospheric CO2 and water vapor peaks. 
Fortunately, this problem can usually be overcome by removing the background contribution, this 
operation is successful if there are no variation in concentrations of atmospheric gas between the 
measurement of the background and the sample spectra (81). 
FTIR spectrometers use an interferometer, usually a four arms Michelson interferometer. The 
top arm contains the infrared source, and a collimating mirror that collects the light from the 
source and makes its rays parallel. The bottom arm contains a stationary mirror, and the right arm 
contains a moving mirror. The left arm contains the sample and detector. At the center of the 
interferometer there is a beamsplitter (Figure 9) (81). 
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Figure 9. The optical diagram of a typical Michelson interferometer. Adapted from (81). 
 
The beamsplitter, a semi-reflecting film, bisects the planes of two mirrors is designed to reflect 
50% of the incident radiation to one of the mirrors and transmit the remaining 50% to the other 
mirror (81,121). After reflecting to the mirrors the two radiation beams recombine and return to 
the beamsplitter. The recombined radiation leaves the interferometer, interact with the sample 
and then reaches the detector (81).  
The detector reads information about every infrared range wavenumber simultaneously. Then, 
the detector signal is sent to the computer and is applied the Fourier transform algorithm that 
converts the interferogram (IFG) into a single beam spectrum, that is a plot of arbitrary infrared 
intensity units versus wavenumber (81).  
To produce an artefact-free transmittance spectrum, removing atmospheric effects and 
instrument contributions, the sample single beam spectrum must be normalized against the 
background spectrum of the air (Figure 10) (81). The obtained transmittance spectrum can be 
converted to absorbance by taking the negative log10 of all the data points (Figure 10) (121,122). 
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Figure 10. The process of collecting an infrared spectrum in an FTIR spectrometer. FT: Fourier 
Transform 
 
1.2.1. The Golden Gate ATRTM, a accessory of sample analysis 
Currently IR-measurements are largely performed in Attenuated Total Reflection (ATR) mode 
because this technique is more versatile and simpler to use than the conventional transmission 
mode. Transmission technique implies that IR beam cross the whole sample, being necessary 
control the sample thickness and opacity. As well as liquid samples are difficult to analyze (121).  
With ATR it is possible to rapidly analyze solids, liquids, powders or pastes samples. In ATR 
sampler the crystal is in contact with the sample, and the IR beam passes through the crystal 
within which it is totally internally reflected beyond the surface of the crystal into the sample in 
contact with the crystal (123). As the sample placed on the crystal absorbs energy, the beam will 
be attenuated or altered. The attenuated beam reaches the detector in the IR spectrometer and 
the information is converter to IR spectra. The absorption (attenuation) of IR beam is proportional 
to chemical concentration of the sample, enabling to extract quantitative  data (120). 
The Golden Gate™ ATR (Figure 11) is one of the most sensitive, robust and versatile infrared 
accessory designed for all the high performance FT-IR spectrometers. The excellent physical 
characteristics of the diamond and the rugged construction of the accessory are the main 
advantage features. The diamond is very resistant and is responsible for the great versatility of 
the Golden Gate™ ATR. Indeed, it can be cleaned quite aggressively, resists to chemical attack and 
thus it is possible the analysis of corrosive liquids, and resists to high loads applied against a solid. 
The diamond also has very good thermal conductivity. This makes it ideal for ATR measurements 
at high or low temperatures because it can be heated or cooled rapidly. Furthermore, its thermal 
conductivity ensures that there are no temperature gradients across the ATR element (124).  
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In addition, the small aperture (2 mm) for placing the sample requires very small sample 
amounts, without or very little need for preparation (124). 
 
 
Figure 11. Golden Gate ATR
TM
 accessory. From (124). 
 
1.2.2. What is shown in infrared spectrum? 
Molecules absorb IR radiation due to the vibrational movements of their chemical bonds. 
Those movements occur at specific energy levels, after IR radiation exposure, the chemical bonds 
absorb IR radiation at wavenumbers correlated to their energy levels. IR spectroscopy measures 
this absorption and, as result, a spectrum is obtained. The peaks (spectroscopic signals) are 
related to specific chemical bonds of functional groups of the sample molecules (116).  
The infrared spectrum is a plot of measured infrared light intensity, which may be presented in 
percent transmittance (%T) or in absorbance (A), versus a property of the radiation, such as a 
wavenumber (cm−1) scale. %T ranges from 0 to 100% and A ranges from 0 to infinity, however the 
peaks should be less than 2 absorbance units or greater than 10% to avoid truncated peaks that 
can compromise the confidence of results, for both qualitative and qualitative analysis (81). 
For qualitative analysis, to identify unknown peaks or perform spectral comparisons can be 
used both of the spectra types, %T or A. For quantitative analysis, spectra must be transformed in 
absorbance because absorbance is linearly proportional to concentration (81). 
1.3. Mid-infrared spectroscopy applied in biological samples  
Most disease diagnoses researches are focused in the mid-infrared region of the spectrum 
(4000 to 400 cm−1) since this region contains many sharp peaks and can provide valuable chemical 
information (83).  
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Mid-infrared spectra between 1800 and 900 cm−1 have a large number of spectroscopic 
information as a result of the absorption of a large number of biochemical molecules (116). 
Therefore, this region may be very useful to characterize biological samples by identifying disease 
biomarkers. However, this kind of samples have great amount of water in their composition that 
absorbs great part of radiation in mid-infrared spectra. The water dilutes the solutes and, in MIR 
spectra, has broad and intense peaks at ranges of 3400-3200 cm-1 and 1700 and 1500 cm-1 that 
can mask the spectroscopic signals of the solutes, thus hindering spectral interpretation. 
1.3.1.  Overcome water overlapping  
The presence of water in biological samples may be minimized by subtracting the spectrum of 
pure water from the spectrum of the sample, this arithmetic operation remove the water signals 
making the peaks of interest much easier to identify. However, a solute in liquid water needs to 
be present in a concentration higher than 0.1% to be detected/identified (81). Another strategy is 
using pure water in the ATR crystal during the acquisition of background single beam. When the 
ratio with the sample single beam is made, the water spectroscopic signals tend to disappear. An 
alternative to overcome this issue is promote the water evaporation and then analyze the 
resulting film. This approach has already been applied on serum samples and, in addition to 
eliminating the spectral interference of water, can provide better spectral resolution in virtue of 
eliminating the water/solute interactions (125). 
The present study is also based on drying methodology to eliminate water contribution but 
under controlled conditions. All the samples are submitted to the same drying time and, to 
control all the process, the spectra are constantly being acquired and recorded. This procedure 
was called drying kinetics and has been used in other biological fluids such as amniotic liquid with 
great results (126). In the present work this procedure was adapted to the serum and plasma 
samples. 
1.3.2. General considerations about  blood samples  
The human blood is a complex fluid matrix of plasma (with high volume of water) and cellular 
components (red blood cells, white blood cells and platelets). For analytical purposes it must be 
performed the immediate separation of plasma or serum from cells to provide analyte stability at 
room temperature (127).  
Plasma is produced when blood with no cells is treated with an anticoagulant, serum is also 
the liquid fraction of whole blood but is collected after the clotting factors being allowed to act. 
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Thus, serum differs qualitatively from plasma because the bulk of the fibrinogen is removed by 
conversion into a fibrin clot together with the platelets. Varying amounts of other proteins and 
other molecules such as RNA (128) are removed into the fibrin clot either by specific or non-
specific interactions (129). So, there are several chemical differences between serum and plasma. 
Serum and plasma are usually considered to have similar compositions and properties. Both 
samples are composed mainly by water, by a complex matrix of low molecular-weight organic 
(lipids, carbohydrates, amino acids and nucleic acids) and inorganic chemicals (Na+, K+, Ca2+, Mg2+, 
Cl2+, HCO3-, HPO4
2- and SO4
2-), combined with other higher-molecular-weight species, including 
proteins (albumins, globulins, regulatory proteins and, only in plasma, fibrinogen) (130). With 
respect to physical characteristics, serum and plasma are usually light yellow in color, odorless, pH 
within the narrow range of 7.35 to 7.45 (slightly basic) and more viscous than water (131). 
According to several studies the use of serum is recommended because of the higher 
instability of plasma analytes (127,132,133). In this study, both samples were study in order to 
compare the results and establish the one that presents the best results to the aim of the study. 
Since water is the main constituent of both plasma and serum, requires that its presence is 
minimized for the analysis by FTIR. In this way it is possible gather reliable information of their 
dissolved constituents. 
2. Method optimization  
2.1. Sample preparation  
In order to optimize the acquisition methodology and to overcome water signals overlap, a 
blood sample from an apparently healthy elderly was used. The sample used belongs to a project 
that was approved by the ethics committee of the Regional Health Center - Coimbra, protocol 
number 012 804 of April 4, 2012. 
All blood samples of this project were received at the laboratory in the range of 30 minutes 
after its collection. Pre-processing was performed immediately. 
From each sample were prepared aliquots of plasma and serum. To obtain plasma, tubes K2 
EDTA 5 mL with gel separator were used. Then a centrifugal force of 1800g, during 15 minutes, at 
8ºC, was applied, wherein the blood cells were separated from plasma. The obtained plasma was 
transferred and resuspended in a tube of 5 ml. For the present study, aliquots of 30 µL of plasma 
were performed that then were stored at -80ºC. 
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Simultaneously serum sample was prepared, tubes of 5 mL with gel separator were used, in 
which blood was allowed to stand approximately 30 minutes. The particularity of this kind of 
tubes is that contains clot activator that accelerates coagulation and removes fibrinogen. Then a 
centrifugal force of 2000g, during 15 minutes, at 8ºC was applied, and the supernatant was 
collected and resuspended in a tube of 5 ml. For this work, aliquots of 30 µL of serum were also 
stored at -80ºC. 
2.2. MIR spectral acquisition  
Samples of plasma/serum were thawed at room temperature and vortexed for 8 seconds 
immediately before spectroscopic analysis. Spectra were acquired with a Perkin-Elmer Spectrum 
BX FT-IRTM spectrometer in the range of 4000-900 cm-1, at resolution of 8 cm-1 with 64 co-added 
scans. During acquisition, room temperature and humidity were kept at ± 25ºC and ± 37% 
respectively. 
For spectral acquisition by drying kinetics the acquisition of background single beam was 
performed against air (with the empty crystal). Then, 8 µL of plasma/serum were placed on the 
ATR crystal (diamond crystal). In this method, the liquid is simply poured onto the crystal that 
should be fully covered. The drying time was achieved and established after approximately 40 
minutes that correspond to the acquisition of 16 consecutive spectra.   
For the arithmetic subtraction of the water spectrum it was necessary to acquire a spectrum of 
water, and spectra of both types of samples (plasma and serum).  
Additionally two spectra (one of plasma and one of serum) were measured, using water during 
the acquisition of background single beam (instead the normal background against air – with the 
empty crystal).  
3. Results  
3.1. Drying Kinetics of serum and plasma 
Figures 12 and 13 show typical sequences of ATR MIR spectra of serum and plasma 
respectively, as a function of drying time. 
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Figure 12. ATR spectra acquired during the drying process (film preparation) of a serum sample. 
Spectroscopic regions mainly associated with the presence of proteins (I) amino acids (I’), lipids (II), 
carbohydrates (III) and DNA/RNA (IV). Adapted from (110,134,135). 
 
Figure 13. ATR spectra acquired during the drying process (film preparation) of a plasma sample. 
Spectroscopic regions mainly associated with the presence of proteins (I) amino acids (I’), lipids (II), 
carbohydrates (III) and DNA/RNA (IV). Adapted from (110,134,135). 
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For both serum and plasma samples, in the beginning (spectra 1), the spectra are dominated 
by the broad water absorption bands at 3400-3200 cm−1 and at 1700-1500 cm−1 due to O-H 
stretching and H-O-H bending respectively (121).  
With the drying kinetics process (Figures 12 and 13) is possible observe bands that gradually 
become much sharper as the water evaporates, mainly in the ranges of broad water signals, 
corresponding to spectroscopic regions directly overlapped with H2O vibrational modes. These 
spectral features correspond to vibrations of functional groups of specific solutes present in 
plasma/serum, mainly proteins (I) and lipids (II). There are other compounds  (carbohydrates (III) 
and DNA/RNA (IV)) whose spectroscopic signals are not directly hidden with water signals but can 
be detected after the drying process (110). This is due to increase of concentration of these 
solutes that naturally occurs when water evaporates. 
Thus, for each sample, after 40 minutes of drying process, it was possible to obtain a spectrum 
with more spectroscopic information and enhanced SNR whose peaks can be assigned, enabling a 
qualitative analysis of the sample. The dried spectra shows apparent contributions of proteins in 
the frequencies range of 3400-3030 cm-1  (135), 1720-1480 cm-1  (110,135) and 1301-1229 cm-1 
(136); lipids in the range of 3020-2819 cm-1 (110), 1750-1725 cm-1 (134) and 1480-1430 cm-1 (110); 
carbohydrates and nucleic acids (DNA/RNA) in the frequencies range of 1200-900 cm-1. In the 
latter region are also detected vibrations of some functional groups of proteins and lipids 
(110,134). 
As showed in the Figures 12 and 13, both samples of plasma and serum give rise to a final 
spectrum with practically the same spectral information. However it is also perceptible that their 
drying patterns differ slightly. For the same atmospheric conditions (temperature and humidity), 
the drying of serum sample proved to be faster than the plasma sample. This can be seen in the 
passage of spectrum 6 to 7 of Figure 12, which contrasts with the more gradual drying of plasma 
sample (Figure 13). Comparing the spectra 7 of both samples, it is possible to observe that the 
peaks in the plasma sample are less defined, which in this case reflect a sample less dry. This small 
difference in the pattern of drying may be due to the fact that plasma be slightly more viscous 
than serum, due to presence of fibrinogen and other compounds absent in serum (137). This 
higher viscosity can be associated with higher intermolecular forces that slow down water 
evaporation. 
Applying principal component analysis (PCA) to compare the 16 spectra of the same sample it 
is possible to ensure that drying was complete and, to identify the identical spectra (Figure 14).  
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Figure 14. PCA scores (a) and loadings (b) of 16 spectra of one sample obtained by dry kinetics. Spt: 
Spectrum 
 
The distribution of samples in PCA enables visualize that the last spectra are very close to each 
other. This allows confirming that little, or none, differences occur between them, and thus it is 
reached the maxim stability of samples. The last three spectra (spectra 14, 15 and 16) were 
completely dry and do not compromise the reproducibility. These will be selected to be later used 
in multivariate analysis at Chapter 3.  
3.2. Comparison of different methods to minimized water signals of 
plasma and serum samples 
Figures 15 and 16 show ATR MIR spectra of serum and plasma, respectively, obtained by three 
possible ways of minimizing water contribution. The first method consists in the arithmetic 
subtraction of water to sample spectrum (spectrum 3), the second method uses pure water in the 
acquisition of the background single beam which is later used to make the ratio with sample 
single beam (spectrum 2), and the third process is based in obtained after drying kinetics of a drop 
of sample (spectrum 1). 
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Figure 15. Comparison of the effect of 3 different methods to minimize water signals of a serum 
sample. 5) Water spectra; 4) Row serum spectrum; 3) Spectrum resulting from the arithmetic 
subtraction of the water spectrum (5) to serum spectrum (4); 2) Spectrum obtained after the acquisition 
of background single beam with water; 1) Typical serum spectrum after drying kinetics. Shaded regions 
contain spectral information of interest, and dashes indicate regions with noise. Regions mainly 
associated with the presence of proteins (I), amino acids (I’), lipids (II), carbohydrates (III) and DNA/RNA 
(IV); A.U – Arbitrary units. Adapted from (110,134,135). 
 
Figure 16. Comparison of the effect of 3 different methods to minimize water signals of a plasma sample. 
5) Water spectra; 4) Row plasma spectrum; 3) Spectrum resulting from the arithmetic subtraction of the 
water spectrum (5) to plasma spectrum (4); 2) Spectrum obtained after the acquisition of background single 
beam with water; 1) Typical plasma spectrum after drying kinetics. Shaded regions contain spectral 
information of interest, and dashes indicate regions with noise. Regions mainly associated with the presence 
of proteins (I), amino acids (I’),  lipids (II), carbohydrates (III) and DNA/RNA (IV); A.U – Arbitrary units. 
Adapted from (110,134,135). 
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In the Figures 15 and 16, it was possible observe that water (spectra 5) clearly dominates the 
overall spectra of plasma/serum samples (spectra 4). This justifies the need to eliminate the water 
signal for further spectral interpretation. 
With all of the 3 methods tested, after water removal, several bands that are absent in the 
spectra 4 of both samples became visible.  After water peaks elimination it is possible to identify 
typical peaks of the major component groups (proteins (I), lipids (II), carbohydrates (III) and 
DNA/RNA (IV)) present in plasma and serum samples. Although it has been shown that spectra 1, 
2 and 3 have almost equivalent information, spectra 1 was the unique spectra that has 
spectroscopic information in all spectral range (4000 – 600 cm-1) and has most intense and 
defined peaks in region of 1800 – 900 cm-1. 
Moreover, the quality of baseline found in the spectra 1, is not observed in the spectra 2 and 
3. In fact these spectra are noisier than spectra 1 as it can be observed in the regions of 4000-
3400 cm-1 and 2300-1800 cm-1, highlighted by dashed rectangles in the Figures 15 and 16. 
In the regions between 3500 and 3000 cm-1 in spectra 2 and 3 are observable negative peaks 
due to the excessive subtraction factor used, showing the subjectivity of these methods in the 
removal of the water contribution. 
Apart from the apparent less subjectivity, the drying kinetics method, even time consuming, 
requires less computational manipulations and the obtained spectra present better SNR than the 
obtained from the methods 2 and 3 that at the first glance would be more desirable because they 
are faster to acquire. 
4. Conclusion 
With drying kinetics it was found a methodology to eliminate the spectral contribution of 
water, maintaining a reasonable signal-to-noise ratio.  
This methodology allows the optimization of the experimental design. That is, by simply 
allowing water to evaporate from the sample, whereas spectra are being acquired, it is possible 
observe changes in spectroscopic signals over time, ensuring that the last spectrum obtained 
reached a constant drying stage. This information is not possible to obtain with the acquisition of 
a single spectrum of the film at the end of the drying process.  
Indeed, the process based in the drying kinetics of a drop of sample proved to be better to 
minimize water contribution in all MIR spectral range than methods of subtraction of water from 
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a direct sample spectrum. For this reason, this was the chosen method for the acquisition of the 
spectra analyzed in Chapter 3.  
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Chapter 3 
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I. Methods of study 
1. Study group 
Inclusion criteria for the study group were: age between 50-90 years, resident in the Aveiro 
region, with complaints including objective memory impairment or other cognitive complains. The 
exclusion criteria were if individuals undergoing chemotherapy or radiotherapy, psychiatric illness 
such as bipolar disorder, schizophrenia, and the use illicit drugs.  
The cognitive evaluation of individuals was carried out at several Centers for Primary Health 
Care in the Aveiro region. The project was approved by the ethics committee of the Regional 
Health Center - Coimbra, protocol number 012 804 of April 4, 2012. 
The Clinical Dementia Rating scale (CDR) (138,139), the Mini-Mental State Examination 
(MMSE) (140), and the Geriatric Depression Scale (GDS) (141,142) were the cognitive testes 
applied to the study group.  
The CDR scale: 0 indicates normal function; 0.5 indicates a transition level (termed 
questionable dementia); 1.0 indicates signiﬁcant loss (almost always a clear correlation with 
dementia); 2.0 indicates loss of moderate cognitive function; 3.0 indicates severe loss. For this 
study cognitive dysfunction was considered when CDR ≥ 0.5.  
The MMSE test permits patient stratification according to the education level: cutoff of 22 for 
0-2 years schoolarship; 24 for 3-6 years; and 27 for more than 7 years (143). Additionally, clinical 
routine questions were included to address other possible neurological pathologies.  
All depressed individuals were excluded using the GDS scale. The GDS (141,142) consists of 15 
questions, to survey for symptoms suggestive of depression, in which individuals with 0-5 positive 
questions were considered normal. 
According to the cognitive evaluation, 17 individuals were subdivided in 3 groups (Table 5): the 
age and sex matched control group (negative for the 3 tests); the putative AD group (positive for 
CDR and MMSE scales, negative for GDS and other neuropathologies) and the other 
neuropathologies group (which includes two individuals with other pathologies or mixed disease 
and therefore also positive for CDR and MMSE scales). 
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Table 5. Characterization of study subjects according to MMSE and CDR scores.  
Sex Age COD MMSE (score) 
Cognitive impairment 
Condition 
MMSE CDR 
F 49 C3 30 - - Control 
F 72 C5 30 - - Control 
F 72 C7 30 - - Control 
F 75 C8 29 - - Control 
F 75 C2 24 - - Control 
F 78 C4 28 - - Control 
M 74 C9 30 - - Control 
M 82 C1 30 - - Control 
F 49 D3 23 + + Putative AD 
F 72 D7 23 + + Putative AD 
F 74 D5 17 + + Putative AD 
F 74 D8 21 + + Putative AD 
F 80 D4 24 + + Putative AD 
M 74 D9 14 + + Putative AD 
M 83 D1 24 + + Putative AD 
F 76 D6 14 + + Other neuropathology 
F 76 D2 20 + + Other neuropathology 
2. Blood samples collection and preparation 
The serum and plasma preparation followed the same procedure stated in Chapter 2 (pg. 43-
44). 
3. Biospectroscopy procedure 
After sample preparation, the spectra were obtained by mid infrared spectroscopy. Then, data 
underwent multivariate analysis to its classification (infer discrimination between putative AD and 
controls) and interpretation (identification of relevant spectroscopic regions and corresponding 
assignments to chemical functional groups).  
3.1. MIR spectral acquisition 
Each spectral acquisition was performed by drying kinetics as stated in Chapter 2 (pg 44). For 
each sample, a total of three independent aliquots (replicates) were recorded. Between 
determinations, the crystal was carefully cleaned with water. 
The temperature and humidity were always controlled and, when it recorded inappropriate 
conditions, the spectra were not acquired. In addition, replicas with discrepant values were 
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removed from the analysis, which led to the final analysis of only a replica. Thus the acquisition of 
three replicates increased the confidence of results, ensuring every eventuality uncontrollable. 
3.2. Data multivariate analysis 
Multivariate analysis methods were used in order to extract information from spectra, and to 
assist in biomedical interpretation. Chemometric methods are diverse and offer different 
approaches to gather specific information from the measured data (Figure 17).  
Multivariate methods can be divided into techniques of multivariate classification (or pattern 
recognition techniques) and of multivariate regression. Techniques of multivariate classification 
can be divided in unsupervised and supervised learning procedures. In unsupervised pattern 
recognition techniques such as principal-component analysis (PCA) and cluster analysis (CA), no a 
priori knowledge about the training set samples (spectra) is required. These methods are used to 
look at the “natural” differences and similarities between spectra. By contrast, supervised pattern 
recognition techniques such as linear discriminant analysis (LDA) and artificial neural networks 
(ANNS) require some a priori knowledge, e.g. clearly identifying samples from disease cases 
versus samples from healthy cases. In this way, supervised procedures allow for a more precise 
classification within the class boundaries, whilst unsupervised methods are useful for an 
exploratory analysis of data (83,144). 
On the other hand, multivariate regression techniques (or multivariate calibration methods), 
are frequently applied to analyze one or multiple constituents in a complex sample that are 
subject to significantly overlapping analytical signals. Among these techniques are principal 
components regression (PCR) and partial least squares regression (PLS) (Figure 1)(145).  
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Figure 17. Most frequently applied multivariate data-analysis techniques in combination with MIR spectroscopic 
methods. MVA: Multivariate data analysis; PCR: Principal component regression; PLS: Partial least-squares regression; 
PCA: Principal-component analysis; CA: Cluster analysis; LDA: Linear discriminant analysis; PLS-DA: Partial least-squares 
discriminant analysis; SIMCA: Soft independent modeling of class analogy; ANNS: Artificial neural networks. Adapted 
from (144). 
 
In this work, PCA is applied to the FTIR-ATR spectra, to find out if the spectral profile of AD 
group has some differences to the spectral profile of control group. In addition, some differences 
and similarities between plasma and serum samples will be discussed. 
3.2.1. PCA analysis 
Previously to multivariate analysis, as stated in Chapter 2, the three last spectra of one 
replicate of each sample were selected and were transferred through JCAMP-DX format into the 
data analysis software developed in the Institut National Agronomique Paris-Grignon in 
collaboration with the University of Aveiro (146).  
Principal Component Analysis (PCA) was applied to the mid-infrared spectra of plasma and 
serum samples in order to extract the main sources of variability. PCA was applied to several 
spectral regions according to some metabolic characteristics related with Alzheimer's pathology 
that are possible identify with FTIR spectroscopy (Table 6), at ranges of 3600–3000, 1800–900 and 
1200–900 cm-1. The region at 875-820 cm-1 was not analyzed, since at this specific region the 
spectra were noisy and results would not be credible. Standard Normal Variate (SNV) was the pre-
treatment applied to all spectral regions; the data set was auto-scaled, to put all of the spectra to 
the same scale (standardize) and increase the differences between they (divided by the standard 
MVA 
techniques 
Multivariate 
classification 
techniques
Unsupervised 
learning 
procedures 
PCA CA
Supervised 
learning 
procedures
LDA PLS-DA SIMCA ANNS
Multivariate 
regression 
techniques
PCR PLS
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deviation). In this work was not used derivative processing since makes loadings interpretation 
difficult and may undermines the confidence of results.  
Table 6. Spectral regions according to some metabolic characteristics related with Alzheimer's pathology.  
Studied regions 
 (cm
-1
) 
Specific bands 
(cm
-1
) 
Assignment Metabolic characteristics of AD Refs 
3600-3000 3600-3100 O–H stretching of 
hydroperoxyl groups 
Lipid oxidation  (147) 
3100-3000 C=C-H indicative of 
unsaturation (olefinic 
band) 
Lipid oxidation  (148) 
1800–900  1750-1725 C=O stretching 
absorption band  
Lipid oxidation (aldehydes, ketons 
and carboxylic acids)  
(147) 
1700-1600 Amide I band Amyloid β-sheet structures 
(changes in the amide I band)  
(74) 
1200-900 1300-1151 Asymmetric PO2
-
 
stretching vibrations 
Signaling alteration  
Phosphorylation of 
carbohydrates and proteins   
(149) 
1149-980 Symmetric PO2
-
 
stretching vibrations 
1000-800 C-O stretching of nucleic 
acids sugars 
DNA/RNA oxidation 
Changes in the DNA/RNA 
backbone  
(150) 
980-950 C-C stretching of DNA 
backbone 
875-820 DNA S-type sugar 
puckering modes  
Epigenetic alterations  
DNA methylation (in cytosines) 
(151) 
 
II. Results and discussion  
1. Spectral analysis 
1.1. Results 
Figures 18 and 19 show spectra of all samples of serum and plasma, respectively. 
58 
 
 
Figure 18. Spectra of all serum samples of putative AD patients and controls, obtained after drying 
kinetics. A.U – Arbitrary units 
 
Figure 19. Spectra of all plasma samples of putative AD patients and controls, obtained after drying 
kinetics. A.U – Arbitrary units 
 
At first glance the spectra appear to be very similar, where it is possible to verify that all 
spectra overlap, without revealing major differences. 
 Figure 20 shows four representative spectra obtained after drying kinetics: two spectra of 
serum – one is of a control subject and the other is of a putative AD patient (spectrum 1 and 2, 
respectively); and two spectra of plasma – one is of a control subject and the other is of a putative 
AD patient (spectrum 3 and 4, respectively). The region at range of 1800-800 cm-1 of the spectra 
was expanded in order to better assign the bands of this region rich in information.  
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Figure 20. 4000-600 and 1800-800 cm
-1
 regions of the FTIR spectra of serum and plasma samples. Serum spectrum of a 
control subject (spectrum 1); Serum spectrum of a putative AD patient (spectrum 2); Plasma spectrum of a control 
subject (spectrum 3); Plasma spectrum of a putative AD patient (spectrum 4). A.U. – Arbitrary units. 
 
The four spectra represented at Figure 20 are very similar amongst them, being impractical 
infer about differences between the control sample and putative AD sample. However it is 
possible try to do the assignments of peaks related with several contents of the serum/plasma. 
Furthermore, in the figure it is possible verify two peaks in both plasma spectra (1342 and 994 
cm-1) that are not present in serum spectra. 
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1.2. Discussion  
Overall spectra appearance: Since the samples are complex mixtures of several compounds 
with multiple functional groups, the overall spectra appearance shows to be complex. This 
complexity often results in several possible assignments of functional groups to the same peak, 
hindering the unequivocal interpretation of spectra. The assignments of bands of Figure 20 were 
made resorting to some group frequency tables (110,120,121,134,152,153). The major content 
assignments for serum and plasma FTIR spectra absorption bands are indicated in Table 7, 
wherein the possible assignments of functional groups are displayed.  
 
Table 7. Spectral assignments of plasma and serum samples.  
Bands (cm
-1
) of spectra of 
plasma and serum 
Major assignments for plasma and serum contents 
Assignments Contents 
 3282 N-H stretching Proteins (Amide A) 
 3088 N-H stretching Proteins (Amide B) 
 2966 C-H asymmetric stretching of CH3 group Lipids (cholesterol esters, 
triglycerides) 
 2944 C-H asymmetric stretching of CH2 group Lipids (long chain fatty acids, 
phospholipids) 
 2872 C-H symmetric stretching of CH3 group Lipids (long chain fatty acids, 
phospholipids) 
 1750 C=O symmetric stretching Lipids (cholesterol esters, 
triglycerides) 
 1636 C=O stretching and N-H in plane bending Proteins (Amide I) 
 1536 and  1516 N-H in plane bending and C-N stretching Proteins (Amide II) 
1474 and 1454 C-H asymmetric bending of CH3 group / C-H 
bending of CH2 group 
Lipids (fatty acids,phospholipids, 
triglycerides) 
1402 COO
-
 stretching Amino acids side chains 
1342* CH2 wagging  Collagen 
 1301 and  1246 N-H bending and C-N stretching Proteins (Amide III) 
1200-900 
 
C-O-C, C-O, C-C, C-O-P, P-O-P vibrations DNA, RNA, carbohydrates, lipids and 
proteins 
 994* C-O ribose, C-C Ribose  
* only present in plasma 
 
Amide vibrations of proteins: The protein backbone shows nine vibrational modes, which 
result in nine fundamental absorption bands specific for proteins, including amide I, II, III, IV, V , VI 
and VII, amide A, and amide B modes (136). The amide IV-VII bands have very low intensities in 
MIR and are not of importance in MIR analyses.  
The two very strong prominent amide absorptions one at 1636 cm-1 essentially due to C=O 
stretching coupled with little in plane N-H bending (less than 20%),  and another at 1536 cm-1 
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due to in plane N-H bending (40-60% of the potential energy) and C-N stretching (18-40%), 
corresponds to Amide I and Amide II bands, respectively (136). These two characteristics 
vibrational modes of proteins are only determined by the secondary structure adopted by the 
polypeptide chain, reflecting the backbone conformation and hydrogen-bonding pattern. The 
amide I band frequency at 1636 cm-1 is assigned to β-sheet conformation of proteins. The 
correlation between secondary structure and frequency of amide II is less simple than for the 
amide I vibration. The slight peak at 1516 cm-1 is also due to Amide II of proteins that have other 
conformation than those with vibrations at 1536 cm-1 (136). Secondary structure is also difficult 
assign to amide III perceptible at peaks of 1301 and 1246 cm-1 attributed to N-H bending and C-
N stretching (135,136). 
After water evaporation, hydrogen-bonded amino groups can dominate the region between 
3400 and 3250 cm-1, wherein the NH stretching vibration gives rise to the amide A band at  3282 
cm-1. The weaker band at 3088 cm-1 from apparent amide B (3100-3030 cm-1) is commonly 
reported as being either an overtone of amide II (NH bend) or a combination mode of amide I and 
amide II that interacts with the strong NH, acquiring enough intensity to be observable through a 
Fermi resonance (FR), resulting in two bands (amide A and amide B) (120,154). 
CH2 and CH3 vibrations: The presence of lipid compounds is suggested by the peaks at 2966 
and 2872 cm-1 due to CH asymmetric and symmetric stretching of methyl group respectively, 
and peak at 2944 cm-1 assigned to CH asymmetric stretching of methylene group. Moreover, the 
bending vibrations of the same hydrocarbons groups are visible at 1474 and 1454 cm-1, also 
supporting the mainly presence of lipids (110,152,153).  
C=O vibrations: The weak band at 1750 cm-1 is most likely related with carbonyl compounds 
absorptions (1750–1725 cm-1) and is probably related with a simple carbonyl compound, such as a 
ketone, an aldehyde, an ester, or a carboxylic acid of lipids (110,152).  
COO- vibrations: The band at 1402 cm-1 is attributable to COO- stretching and also suggests 
the presence of amino acids in plasma and serum (110,155). 
“Fingerprint region”(1200-900 cm-1): Bands at region of 1200-900 cm-1 are due to C-O-C, C-O, 
C-C, C-O-P, P-O-P vibrations of DNA, RNA, carbohydrates, lipids and proteins (156). Some 
substances at this region present some specific signatures that enable its rapid identification, so it 
is also called fingerprint region. In complex mixtures such as serum/plasma these features are 
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very difficult to observe, and the undoubted assignment of bands is often impractical, occurring 
by deduction. 
In all spectra is possible to visualize the probable contributions of lipids, proteins, amino acids, 
carbohydrates and small molecules of low abundance present in plasma and serum samples. 
Moreover, it is observable slight differences between plasma and serum spectra at 1342 and 
994 cm-1. These bands are only observable in plasma samples. The weak band at 1342 cm-1 is 
maybe due to CH2 wagging of collagen (134). Collagen is an abundant protein present in 
endothelial layer of blood vessels and, when vessels are damaged for example due to needle prick 
during blood collection, collagen is exposed to flowing blood. Collagen is thought to function as a 
substrate for the adhesion and activation of platelets and also initiates the clotting process by 
activating Hageman factor (factor XII of coagulation). Both the activation of platelets and the 
activation of factor XII lead to thrombin generation, which converts fibrinogen into fibrin and that 
constitute the blood clot (157). Since that serum is the fraction of blood collected after the 
clotting factors being allowed to act, it has no collagen and other proteins because they are 
removed in clot. The band at 994 cm-1 in plasma spectra (3 and 4) is probably due to ring 
vibrations of ribose of RNA (134). RNA that is released when tissue is damage is thought to 
promote blood clotting. Further, it was shown large concentrations of RNA retained in the clot 
(128). These findings may justifies the presence of band at 994 cm-1 in spectra 3 and 4, 
suggesting higher concentrations of RNA in the plasma than in serum. However, it can also be due 
to D-ribose vibration that is a monosaccharide essential to obtain energy, suggesting that the 
plasma concentrations of this monosaccharide is greater than the serum. 
Although visual interpretation of the spectra allows some distinction between serum and 
plasma samples, it proved insufficient to distinguish between the spectrum of the control sample 
and the spectrum of the putative AD patient. Therefore, taken into account its ability to withdraw 
more information of the data, multivariate analysis was used to highlight differences between the 
study groups (putative AD vs control) in both samples of serum and plasma.  
2. Multivariate analysis 
FTIR experiments consist of the results of observations of many variables for a number of 
samples. Each variable may be regarded as constituting a different dimension, such that if there 
are n variables each object may be said to reside at a unique position in an abstract entity 
63 
 
referred to as n-dimensional hyperspace. This hyperspace is difficult to visualize, and the 
multivariate data analysis (MVA) allows reduce the data dimensionality, being possible to have a 
better perception of the data, with the least possible loss of information (83). PCA is probably the 
most widespread multivariate chemometric technique that most significantly changed the 
chemist’s examination of spectroscopic data. 
2.1. Results  
The purpose of PCA analysis is verify if there are a short number of new variables – principal 
components (PCs) – that explain a high percentage of total variation associated with the original 
set, without sacrificing information relevant. This is performed through a transformation of the 
original data matrix with each wavenumber (variable) being a column and each spectrum 
(sample) a row. This transformation gives rise to two types of diagrams: diagram of factorial 
coordinates (scores) and diagram of factorial contributions (loadings). Scores contain information 
on how the spectrum relate to each other. Loadings contain information on how the 
wavenumbers relate to each other and, thus, justify the sample distribution along the scores 
diagram (116). PCs are ordered so that PC1 exhibits the greatest amount of variation, PC2 the 
second greatest amount of variation and so on. In this way, PCA allows as much as possible of the 
variance in the data set to be described by the first significant PCs, while all subsequent PCs are so 
low as to be virtually negligible (158). 
The average spectra from each group to remove the peaks which distinguish them may mask 
important spectral values, which characterize certain samples. When using the PCA, this trend is 
eliminated because the information contained in the PCA loadings gives spectral information that 
allows distinguishing groups with the least possible loss of information, taking into account all 
samples. 
PCA was applied to the spectral regions of 3600-3000, 1800–900 and 1200-900 cm-1. The 
region at 3600-3000 cm-1 that could give the information related to lipid peroxidation (Table 6), 
showed no discrimination capable to be explained in accordance with the assumption initial. The 
samples are shuffled and loadings are too noisy (Figures 21 and 22).  
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Figure 21. PCA scores (Aa) and loadings (Ab) of serum samples (3600-3000 cm
-1
 range). 
 
Figure 22. PCA scores (Ba) and loadings (Bb) of plasma samples (3600-3000 cm
-1
 range). 
 
The region at 1800-900 cm-1 could also give relevant information (Table 6), mainly about lipid 
oxidation and amyloid β-sheet structures (1700-1600 cm-1), as well as alterations in the backbone 
of DNA/RNA and nucleic acids, and phosphorylation of carbohydrates and proteins (1300-900 cm-
1). Figures 23 and 24 show PCA of the spectral region between 1800 and 900 cm-1. 
 
Figure 23. PCA scores (Aa) and loadings (Ab) of serum samples (1800-900 cm
-1
 range). 
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Figure 24. PCA scores (Ba) and loadings (Bb) of plasma samples (1800-900 cm
-1
 range). 
 
The region at 1800-900 cm-1 is very information rich and shows some tendency to form two 
main groups, one mainly explained by the negative side of PC1 and another mainly explained by 
the positive side of PC1. However, the corresponding loadings profile diagram proved to be noisy 
(mainly in plasma samples) and complex to interpret at range of 1800-1400 cm-1. In addition, the 
separation of groups could be better, seeming to reveal little information to the aim of the study. 
Therefore, it was necessary to reduce the spectral region in order to find the one that best fit with 
the study propose. As shown in PCA loadings, the region between 1400 and 1200 cm-1 has little 
spectroscopic information (Figure 23 Ab and 24 Bb). To the contrary, 1200 and 900 cm-1 region is 
rich in spectral information (Figure 23 Ab and 24 Bb) that can be related with carbohydrates 
structures, phosphate groups, and various vibrations of amino acids, which in turn can be related 
with some pathologic processes of Alzheimer’s disease (Table 6). This specific region was also 
analyzed through PCA (Figure 25 and 26). 
 
Figure 25. PCA Scores (Aa) and loadings (Ab) of serum samples (1200-900 cm
-1
 range). 
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Figure 26. PCA Scores (Ba) and loadings (Bb) of plasma samples (1200-900 cm
-1
 range). 
 
Three groups may be suggested based on the distribution of samples along PC1 that explains 
most the variability, and PC2, which conveys the second most important factor of the remaining 
analysis. Serum and plasma have practically the same information, but serum has a better 
discrimination.  
In both serum and plasma (Figure 25Aa e 26Ba) it can be observed that one group of putative 
AD patients – gAD1 – is mainly distributed in Q2 and Q3 and is constituted by D1, D4, D6 and D8; 
another group of patients – gAD2 – is mainly distributed in the Q1 and Q4 and include D5, D3 and 
D9. The patient D2 seems to be an outlier, based on the analysis of both samples of serum and 
plasma, because it is not close to any study group. The patient D7 is located very close to controls. 
The group of controls – gC – is distributed close to zero of both PCs, as a result is slightly less 
affected by the peaks identified in PCA loadings. Group gC is constituted by C1, C2, C3, C4, C5, C7, 
C8 and C9. In plasma (Figure 26Aa), the control C7 seems to be influenced by any plasma 
characteristics that somehow prevent its position in gC, as clearly occur in serum (Figure 25Ba). 
The examination of the loadings is useful to understand the basis of the observed separation 
of the samples. Table 8 shows the possible assignments of the peaks selected in the PCA loadings 
(Figure 25Ab and 26Bb) that reflect the peculiarities of the sugar-phosphate skeleton of nucleic 
acids and carbohydrates. 
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Table 8. MIR bands between 1200 and 900 cm
-1
 range identified in PCA loadings. 
Serum bands (cm
-1
) Plasma bands  (cm
-1
) Assignments AD 
group 
1170 1170 C-OH stretching of amino acids (serine, threonine, and 
tyrosine)  
gAD2 
1140 1140 C-OH bonds in oligosaccharides  gAD1 
1104 1104 C-O stretching of glucose gAD1 
1094 1094 Symmetric stretching of PO2
-
 of phosphodiesters gAD2 
1074 1074 Symmetric stretching of PO2
-
 of phosphodiesters gAD1 
1064 1064 C-O stretching of ribose gAD2 
1030 1030 C-O stretching of glucose gAD1 
992 992 C-O ribose, C-C gAD1 
932 932 C-O/ C-C  stretching of deoxyribose  gAD2 
 
 
2.2. Discussion 
Group gAD1: possible coexistence of Alzheimer’s disease and vascular pathology 
The analysis of PCA scores shows that patient D1, D4, D6 and D8 are very close to each other. 
This proximity is justified by peaks at 1104 and 1030 cm-1 that was related with glucose vibrations 
(159) and peak at 1140 cm-1 due to C-OH bonds in oligosaccharides (160). Peak at 1074 cm-1 is 
may be due to symmetric stretching of PO2
- (134). The other peak common to patients of this 
group is at 992 cm-1 due to ring vibrations of ribose. 
Vibrations of carbohydrates suggest that they are altered in patients of gAD1 group and high 
levels of carbohydrates are hallmarks of DM (161). DM 2 type and AD are considered age-related 
diseases, and several studies report that patients with diabetes have an increased risk of 
developing AD (two to five times) compared with healthy individuals (40,41). Elderly patients with 
diabetes develop more extensive vascular pathology, which together with AD hallmarks, results in 
increased dementia risk (36,162). Patients D1, D4 and D6 suffer from DM, and the whole group 
report hypertension, which, together with  advanced aging and DM, are vascular risk factors to 
develop degeneration in cerebral capillaries (35). This vascular damage can converge to create 
a cerebral hypoperfusion state – CATCH – that impairs optimal delivery of glucose needed for 
normal brain cell function. The outcome of this defect generates a cascade of events leading to 
the progressive evolution of brain metabolic, cognitive and tissue pathology that characterize 
Alzheimer’s disease (42).  
Moreover, brain insulin resistance that promotes neuro-inflammation and increased 
expression of Aβ, can be caused by peripheral insulin resistance due to DM 2 type, which in turn is 
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also correlated with increase tau hyperphosphorylation, NTFs and subsequent neurodegeneration 
(39). This suggests a closely relation between DM 2 type and AD.  
Hyperglicemia promotes protein glycation and the gradual accumulation of AGEs (40). A 
glycated protein loses its function, is more susceptible to oxidative damage, and is more resistant 
to degradation and removal. Glycation and oxidation of Aβ convert it into an oligomeric complex 
with reduced susceptibility to degradation by the lysosomes. This resistance of Aβ to degradation 
invokes the rapid ROS generation within lysosomes leading to a lysosomal general dysfunction, 
which progress to mitochondrial dysfunction and subsequent neuronal death (40).  
The vibrations of carbohydrates at 1140, 1104 and 1030 cm-1 may be due to high levels of 'free' 
sugars in plasma/serum, AGEs, and/or glycoxidation. The vibrations of ribose ring at 992 cm-1 can 
be due to ‘free’ D-ribose, an monossacaride essential to production of energy, that also 
participates in the proteins glycation (also called ribosylation) producing AGEs, that may be 
involved in cell dysfunction and subsequent cognitive impairments (163). 
Oxidative stress is prominent in the onset of AD (164) due to several dysfunctional 
mechanisms (41). The subsequent outcome is the damage of cellular biomolecules such as lipids, 
proteins, nucleic acids, and sugars, leading to posterior cellular dysfunction and death (40). 
Structural alteration of nucleic acids affects the vibrational dynamics of these molecules. ROS, and 
particularly hydroxyl radical, can react with all components of the DNA molecule, causing 
different kinds of damage. Free radicals can directly attack phosphodiester-deoxyribose moiety, 
abstracting a hydrogen atom from the sugar component and yield a wide variety of products 
(165). Ribose vibration at 992 cm-1 can also be due to alterations of ribose of RNA as consequence 
of oxidative damage. Strand breaks and loss of phosphoric acid are also causes of ROS attack (165) 
and increase the degrees of freedom of the molecule (150). The vibrations of phosphate groups 
suggested by peak at 1074 cm-1 may be due to breaks in DNA/RNA backbones.  
Patient D6 of gAD1 group reveals visual hallucinations at clinical evaluation suggesting the 
presence of dementia with Lewy Bodies. However, hallucinations are also common after mini-
stocks due to vascular pathology.  Indeed, its metabolic proximity to putative AD patients suggests 
a mixed dementia for AD and DLB or AD and vascular pathology that are both common conditions 
(1).  
Having said this, it was shown that gAD1 have a metabolic profile consistent with clinical 
information, neuropsychologic tests and pathogenesis of AD that suggest a possible coexistence 
of AD and vascular pathology. Glycation is suggested by peaks at 1140, 1104, 1030 and 992 cm-1 
and oxidative damage is suggested by peaks at 1074 and 992 cm-1. According to our knowledge, 
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the absorptions related with carbohydrates in relation with AD are presented here for the first 
time. 
 Group gAD2: possible pure Alzheimer’s disease  
Analysis of scores demonstrated that the group gAD2 and gC are both in positive side of PC1. 
However, gAD2 is farther from the center axis of the PCA than group gC, so it is more strongly 
affected by variables that justify the disposition of samples in the positive side of PC1. Distribution 
of the gAD2 group is strongly justified by four peaks: 1170 cm-1 due to C-OH stretching of amino 
acids such as serine, threonine, and tyrosine (134); 1094 cm-1, due to symmetric PO2− stretching of 
DNA/RNA backbone (134); 1064 cm-1 due to ribose vibration (C-O/C-C) (134); and 932 cm-1 due to 
deoxyribose vibration (C-O/C-C) (134).  
Among several interveners that contribute to neuronal loss and progression of damage and 
cognitive decline in AD, oxidative stress and signaling pathways alteration such as protein hyper-
phosphorylation have received great attention by researchers (31,33,34,166,167).  
The peak at 1170 cm-1 suggests that there are certain alterations in proteins that somehow 
alter their conformation, affecting the exhibitions of amino acids such as serine, threonine, and 
tyrosine. This conformational alteration may be due to oxidative damage of proteins or 
phosphorylation of proteins. A variety of AD associated proteins (APP, BACE, PS and tau) are 
shown to be phosphorylated (33), wherein tau has been shown to be abnormally hyper-
phosphorylated at several serine/threonine residues in AD (166), and phosphorylation of serine 
residues in β-sheet conformation of Aβ was also proved (166). In turn, all of amino acids can be 
attacked by ROS, but aromatic amino acids such as threonine are highly susceptible (31). 
Therefore, oxidation of amino acids can be other cause of protein alteration suggested by peak at 
1170 cm-1. 
Damage of structural backbone of DNA/RNA probably induced by ROS is suggested by peaks at 
1094, 1064 and 932 cm-1. Peaks at 1064 and 932 cm-1 may represent the alteration of sugar of 
nucleic acids and peak at 1094 cm-1 due to symmetric PO2
− stretching may be due to strand breaks 
and loss of phosphoric acid.  
In sum, it was shown that gAD2 have also a metabolic profile consistent with clinical 
information, neuropsychologic tests and pathogenesis of AD, suggesting a dementia only due to 
AD. The gAD2 group is highly justified by spectroscopic findings at 1094, 1064 and 932 cm-1 
related with oxidative damage, as verified in other similar study (113), and by peak at 1170 cm-1 
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related with protein alteration (maybe by phosphorylation or oxidation) that seems to be related 
with AD for the first time.  
Common points of the two AD groups  
Oxidative damages are suggested in both gAD1 and gAD2, which suggest that both of them are 
related with metabolic profiles that present oxidative stress and allow their distinction from 
control group.  
ROS are also reactive with nucleotide bases, but vibrations of these structures are not seen in 
this spectral region, but between 1750 and 1300 cm-1 (165). The breaks of DNA can give rise to 
oxidized DNA bases such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) (31). The high levels of 8-
OHdG were found in AD plasma samples and were also related with similar spectroscopic results 
to those obtained here (113). In turn, RNA is more vulnerable to oxidation than DNA and levels of 
8-hydroxyguanosine (8-OHG) was associated as a marker of oxidative damage to RNA (31). 
Indeed, significant levels of 8-OHdG and 8-OHG were found in patients with MCI (168,169), 
indicating that oxidative damages of DNA and RNA are early events in the pathogenesis of AD, and 
that in turn the FTIR may be useful to detect this early events.  
Complementary analysis 
Alzheimer's disease is a multifactorial disease with multiple biochemical consequences, and 
certain vibrations that characterize disease samples can be masked by others vibrations, thus can 
approximate it to the control group.  
Since gAD1 disposition is affected mainly by alterations of carbohydrates and D1, D4 and D6 
are diabetics, one possibility is that metabolic profile of these patients can mask some 
characteristics of D7, which prevents that it deviates from the control group. Thus, to test this 
possibility, diabetic patients (D1, D4 and D6) were removed to attenuate its interference (Figure 
27 and 28).   
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Figure 27. PCA scores (Aa) and loadings (Ab) of serum samples, without D1, D4 and D6 (1200-900 cm
-1
 
range). 
 
Figure 28. PCA scores (Ba) and loadings (Bb) of plasma samples, without D1, D4 and D6 (1200-900 cm
-1
 
range). 
With this new analysis is possible observe that three initial proposal groups and loadings 
profile remain the same. The disposition of patient D8 (gAD1’) in PCA scores is highly justified by 
the same peaks of the initial gAD1 group (1140, 1074, 1030 and 992 cm-1). This also suggests that 
these peaks highly characterize gAD1, which is associated to glycation and oxidative stress that 
also occurring in AD patients that are non-diabetics but have alterations in carbohydrates. 
One of two things, either patient D8 (i) may have recent ingestion of food compared to all 
other subjects in study, or (ii) can be a pre-diabetic. First situation suggest that carbohydrates 
profile can mask peaks that justify AD presence in gAD1 and only signals of carbohydrates due to 
its high concentration are present. This hypothesis has to be considered, since it was not possible 
to have biochemical information and volunteers are not necessarily fasting. However it is very 
remote, since it is unlikely that only the patient D8 has high carbohydrate levels due to recent 
ingestion of food. The last situation supports the possibility of a relation between AD, DM and 
hypertention – coexistence of AD with vascular pathology – because D8 is a putative AD with 
hypertension and is close to diabetic patients.   
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An obvious distinction between gAD2 and control group is also shown in Figure 27, this 
distribution is justified by the same peaks (1170, 1094, 1064 and 932 cm-1) indicating that this 
group is highly affected by oxidative stress and/or protein phosphorylation. 
Moreover, given its permanent proximity to controls, the patient D7 is either a putative AD 
patient influenced by other wavenumber profile or a probable false positive to AD. Finally, this 
new analysis allows seeing that patient D2 is clearly an outlier. 
Regarding to D2, it is suggested to be a probable patient with PDD or DLB, since he reveals 
Parkinsonism and hallucinations at the clinical evaluation. In addition, its spectral information is 
not close to any group. This evidence suggests that this patient is characterized by other peaks 
other than those characterizing the groups of putative AD. In order to test little influence of D2 in 
results, he was removed to the study (Figure 29 and 30).   
 
Figure 29. PCA Scores (Aa) and loadings (Ab) of serum samples, without D2 (1200-900 cm
-1
 range). 
 
Figure 30. PCA Scores (Ba) and loadings (Bb) of plasma samples, without D2 (1200-900 cm
-1
 range). 
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Comparing this new analysis with Figures 25 and 26, it is possible to show that, in both plasma 
and serum, gAD2 has now less intra-class variability, which suggests that D2 adds a little variability 
to the gAD2. However, in general, the D2 not hides nor the loadings or the scores, so the peaks 
that justify each AD group are the same.  
III. Conclusion 
It was established conditions of analysis for serum and plasma samples. Using FTIR 
spectrometer at resolution of 8 cm-1 with 64 co-added scans to the spectral acquisition and 
resorting to drying kinetics to the water removal it was possible obtain spectra with reasonable 
SNRs, which allowed good spectral interpretation and subsequent multivariate approach. The 
drying time was achieved after 40 minutes with little amount of sample (8 µL), in atmospheric 
controlled conditions. 
With direct analysis of spectra it was possible identify the main bands of spectra of serum and 
plasma between 4000-600 cm-1. Although this analysis allows some distinction between serum 
and plasma samples, proved to be insufficient to distinguish the spectra of the control samples of 
the spectra of putative AD patients. This is due to intrinsic complexity of biological samples that 
result in several overlaps of absorptions of the main biomolecules, in IR spectra. Therefore, to 
draw out the significant and nonredundant information contained in these highly dimensional 
data is required the support of an appropriate multivariate analysis approach. 
Multivariate analysis of data highlights differences between putative AD patients and controls 
matched by age and sex. In fact, with both serum and plasma, three groups were suggested by 
PCA scores analysis in range of 1200-900 cm-1. PCA loadings profile revealed biochemical 
modifications in serum/plasma of putative AD patients probably related to oxidative stress 
according to other similar studies, protein alteration maybe by phosphorylation or oxidation and 
glycation that seems be suggested for the first time. In addition, results also suggest that other 
neuropathological conditions, either in a mixed condition with AD (gAD1) or not (D2), may have 
different profiles than pure AD (gAD2). With effect, the results showed that identification of 
functional groups maybe associated to biomarkers is only suitable with a combination of 
spectroscopy and of multivariate analysis. 
The information obtained from plasma and serum is quite similar, with no large differences 
both in scores and in loadings. Serum scores scatter plot provide better discrimination between 
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putative AD and control samples and loadings profile plasma does not provide additional 
spectroscopic information that may lead to the identification of biomarkers. Serum proved to be 
more suitable for a further study.  
Although the small sample size has limited the biological relevance of the results, this 
qualitative data served effectively as a first step to more intensive and targeted confirmatory 
experiments in the future.  
This pilot study showed that dry serum/plasma samples, with posterior IR spectroscopic 
analysis and PCA are an interesting routine of methods for AD evaluation. In turn, IR spectroscopy 
reveals to be a potential multi-biomarker technique to a rapid diagnosis of AD, even in early states 
of cognitive impairment. It was proved to be very convenient because is reagent free, requires 
small amount of samples, is cost effective, simple to perform, provides real time results and, with 
proper customization, do not need of highly qualified technician. 
IV. Limitations and future remarks 
This pilot study, with such as promising results, needs to be continued. It is imperative to 
increase the data set and to build a robust AD classification model that should be validated with 
an independent and unequivocally classified data set. 
Given the intrinsic complexity of biological systems, some overlaps of absorptions occur, 
masking relevant information. In order to deep understand the AD pathology and to further 
identify AD related biomarkers, purifications of specific molecules could be a close approach, 
specifically to analyze evidence of damage of nucleic acids and protein phosphorylation. It would 
also be an upcoming challenge, supplement the results obtained with a more specific 
metabolomic techniques, such as Mass Spectrometry or Nuclear Magnetic Resonance. 
Apart from a good characterization of the volunteers, that proved to be essential to obtained 
consistent results, other information of patient samples would be useful to correlate with FTIR 
data, including biochemical analysis of glucose, cholesterol and markers of oxidation and 
antioxidation. To eliminate external variables related to the intake of carbohydrates that affects 
the 1200-900 cm-1 profile, it would be advisable to collect blood from patients after an overnight 
fast. 
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